|
US513030A
(en)
|
|
1894-01-16 |
|
Machine for waxing or coating paper |
|
US2878264A
(en)
|
|
1959-03-17 |
|
Substituted amino alcohols |
|
CH372667A
(de)
|
1957-09-26 |
1963-10-31 |
Robins Co Inc A H |
Verfahren zur Herstellung von 3-Aryl-3-pyrrolidinolen
|
|
US3135766A
(en)
|
1961-10-03 |
1964-06-02 |
Mead Johnson & Co |
3-substituted-3-pyrrolidinols
|
|
US3484473A
(en)
|
1967-05-12 |
1969-12-16 |
Buckman Labor Inc |
Methylene bisesters of thiolsulfonic acids
|
|
DE1934150A1
(de)
|
1968-07-10 |
1970-01-15 |
Pennwalt Corp |
Neue 1-Alkanoyloxy-1,2,4,5-tetrahydro-3H,3-benzazepine
|
|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
US3745162A
(en)
|
1970-08-31 |
1973-07-10 |
Robins Co Inc A H |
1,2,3,4-tetrahydroisoquinoline-2-(thio)-carboxamides
|
|
GB1448437A
(en)
|
1973-02-24 |
1976-09-08 |
Beecham Group Ltd |
Diphenylpropylamines
|
|
US4022791A
(en)
|
1975-06-03 |
1977-05-10 |
Pfizer Inc. |
2-Aminomethyl-3,4-dihydronaphthalenes
|
|
GB1504424A
(en)
|
1975-08-09 |
1978-03-22 |
Beecham Group Ltd |
Isoquinoline-derived aminoethers
|
|
BR7807288A
(pt)
|
1977-11-08 |
1979-06-12 |
Genentech Inc |
Processo para sintese de polinucleotidos
|
|
DD133885B1
(de)
|
1978-01-04 |
1981-02-25 |
Hans Lehmann |
Mittel zur bekaempfung von phytopathogenen bakterien und pilzen
|
|
US5132418A
(en)
|
1980-02-29 |
1992-07-21 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US4500707A
(en)
|
1980-02-29 |
1985-02-19 |
University Patents, Inc. |
Nucleosides useful in the preparation of polynucleotides
|
|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US4415732A
(en)
|
1981-03-27 |
1983-11-15 |
University Patents, Inc. |
Phosphoramidite compounds and processes
|
|
US4973679A
(en)
|
1981-03-27 |
1990-11-27 |
University Patents, Inc. |
Process for oligonucleo tide synthesis using phosphormidite intermediates
|
|
US4668777A
(en)
|
1981-03-27 |
1987-05-26 |
University Patents, Inc. |
Phosphoramidite nucleoside compounds
|
|
US4542142A
(en)
|
1982-11-22 |
1985-09-17 |
Roussel Uclaf |
Insecticidal cyclopropane carboxylic acid derivatives with 3-unsaturated-side chain
|
|
DE3329892A1
(de)
|
1983-08-18 |
1985-03-07 |
Köster, Hubert, Prof. Dr., 2000 Hamburg |
Verfahren zur herstellung von oligonucleotiden
|
|
US5118800A
(en)
|
1983-12-20 |
1992-06-02 |
California Institute Of Technology |
Oligonucleotides possessing a primary amino group in the terminal nucleotide
|
|
US5643889A
(en)
|
1984-07-11 |
1997-07-01 |
Temple University-Of The Commonwealth System Of Pennsylvania |
Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
|
|
FR2567892B1
(fr)
|
1984-07-19 |
1989-02-17 |
Centre Nat Rech Scient |
Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
|
|
US5367066A
(en)
|
1984-10-16 |
1994-11-22 |
Chiron Corporation |
Oligonucleotides with selectably cleavable and/or abasic sites
|
|
FR2575751B1
(fr)
|
1985-01-08 |
1987-04-03 |
Pasteur Institut |
Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
|
|
FR2576898B1
(fr)
|
1985-02-01 |
1988-01-08 |
Lafon Labor |
Derives de 3-phenyl-tetrahydropyridine, procede de preparation et utilisation en therapeutique
|
|
US4659774A
(en)
|
1985-11-01 |
1987-04-21 |
American Hoechst Corporation |
Support for solid-phase oligonucleotide synthesis
|
|
US4735949A
(en)
|
1986-02-18 |
1988-04-05 |
Warner-Lambert Company |
Disubstituted-7-pyrrolidinonaphthyridine antibacterial agents
|
|
US4840956A
(en)
|
1986-02-18 |
1989-06-20 |
Warner-Lambert Company |
Novel disubstituted-7-pyrrolidinoquinoline antibacterial agents
|
|
IL83663A0
(en)
|
1986-10-27 |
1988-01-31 |
Robins Co Inc A H |
Preparation of 3-pyrrolidinols
|
|
JP2828642B2
(ja)
|
1987-06-24 |
1998-11-25 |
ハワード フローレイ インスティテュト オブ イクスペリメンタル フィジオロジー アンド メディシン |
ヌクレオシド誘導体
|
|
ES2045028T3
(es)
|
1987-07-30 |
1994-01-16 |
Univ Bar Ilan |
Esteres de acidos carboxilicos biologicamente activos.
|
|
US4923901A
(en)
|
1987-09-04 |
1990-05-08 |
Millipore Corporation |
Membranes with bound oligonucleotides and peptides
|
|
US5175273A
(en)
|
1988-07-01 |
1992-12-29 |
Genentech, Inc. |
Nucleic acid intercalating agents
|
|
US4945158A
(en)
|
1988-08-12 |
1990-07-31 |
American Cyanamid Company |
Antidiabetic phosphonates
|
|
US4943629A
(en)
|
1988-08-12 |
1990-07-24 |
American Cyanamid Company |
Antidiabetic alpha-substituted phosphonates
|
|
US5047524A
(en)
|
1988-12-21 |
1991-09-10 |
Applied Biosystems, Inc. |
Automated system for polynucleotide synthesis and purification
|
|
US5262530A
(en)
|
1988-12-21 |
1993-11-16 |
Applied Biosystems, Inc. |
Automated system for polynucleotide synthesis and purification
|
|
US5141813A
(en)
|
1989-08-28 |
1992-08-25 |
Clontech Laboratories, Inc. |
Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis
|
|
US5134066A
(en)
|
1989-08-29 |
1992-07-28 |
Monsanto Company |
Improved probes using nucleosides containing 3-dezauracil analogs
|
|
CA2029273A1
(en)
|
1989-12-04 |
1991-06-05 |
Christine L. Brakel |
Modified nucleotide compounds
|
|
US5130302A
(en)
|
1989-12-20 |
1992-07-14 |
Boron Bilogicals, Inc. |
Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
|
|
AU658134B2
(en)
|
1989-12-28 |
1995-04-06 |
Virginia Commonwealth University |
Sigma receptor ligands and the use thereof
|
|
US7101993B1
(en)
|
1990-01-11 |
2006-09-05 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides containing 2′-O-modified purines
|
|
US5635488A
(en)
|
1991-10-15 |
1997-06-03 |
Isis Pharmaceuticals, Inc. |
Compounds having phosphorodithioate linkages of high chiral purity
|
|
US6339066B1
(en)
|
1990-01-11 |
2002-01-15 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
|
|
EP0604409B1
(en)
|
1990-01-11 |
2004-07-14 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs for detecting and modulating rna activity and gene expression
|
|
US5457191A
(en)
|
1990-01-11 |
1995-10-10 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
|
US5852188A
(en)
|
1990-01-11 |
1998-12-22 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having chiral phosphorus linkages
|
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
|
US5620963A
(en)
|
1991-10-15 |
1997-04-15 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
|
|
US5914396A
(en)
|
1990-01-11 |
1999-06-22 |
Isis Pharmaceuticals, Inc. |
2'-O-modified nucleosides and phosphoramidites
|
|
US5212295A
(en)
|
1990-01-11 |
1993-05-18 |
Isis Pharmaceuticals |
Monomers for preparation of oligonucleotides having chiral phosphorus linkages
|
|
US5587361A
(en)
|
1991-10-15 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
|
US5506212A
(en)
|
1990-01-11 |
1996-04-09 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides with substantially chirally pure phosphorothioate linkages
|
|
US5646265A
(en)
|
1990-01-11 |
1997-07-08 |
Isis Pharmceuticals, Inc. |
Process for the preparation of 2'-O-alkyl purine phosphoramidites
|
|
US5587470A
(en)
|
1990-01-11 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
|
US5036964A
(en)
|
1990-03-28 |
1991-08-06 |
Dana Corporation |
Armature assembly for an electromagnetic coupling
|
|
US5292875A
(en)
|
1990-04-20 |
1994-03-08 |
Lynx Therapeutics, Inc. |
Method of synthesizing sulfurized oligonucleotide analogs
|
|
US5151510A
(en)
|
1990-04-20 |
1992-09-29 |
Applied Biosystems, Inc. |
Method of synethesizing sulfurized oligonucleotide analogs
|
|
ES2139578T3
(es)
|
1990-05-23 |
2000-02-16 |
Isis Pharmaceuticals Inc |
Composiciones y procedimiento para modular la actividad del arn mediante la modificacion de la estructura protectora 5' del arn.
|
|
US5677437A
(en)
|
1990-07-27 |
1997-10-14 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
|
US5688941A
(en)
|
1990-07-27 |
1997-11-18 |
Isis Pharmaceuticals, Inc. |
Methods of making conjugated 4' desmethyl nucleoside analog compounds
|
|
US5541307A
(en)
|
1990-07-27 |
1996-07-30 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs and solid phase synthesis thereof
|
|
US5783682A
(en)
|
1990-07-27 |
1998-07-21 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide mimics having nitrogen-containing linkages
|
|
US5138045A
(en)
|
1990-07-27 |
1992-08-11 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
|
WO1994022886A1
(en)
|
1993-03-30 |
1994-10-13 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
|
US5834607A
(en)
|
1990-07-27 |
1998-11-10 |
Isis Pharmaceuticals, Inc. |
Amines and methods of making and using the same
|
|
US6087482A
(en)
|
1990-07-27 |
2000-07-11 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
|
US5792844A
(en)
|
1990-07-27 |
1998-08-11 |
Isis Pharmaceuticals, Inc. |
Oligonucleoside linkages containing adjacent nitrogen atoms
|
|
US5602240A
(en)
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
|
US5489677A
(en)
|
1990-07-27 |
1996-02-06 |
Isis Pharmaceuticals, Inc. |
Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
|
|
US5610289A
(en)
|
1990-07-27 |
1997-03-11 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogues
|
|
US5614617A
(en)
|
1990-07-27 |
1997-03-25 |
Isis Pharmaceuticals, Inc. |
Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
|
|
US5386023A
(en)
|
1990-07-27 |
1995-01-31 |
Isis Pharmaceuticals |
Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
|
|
US5618704A
(en)
|
1990-07-27 |
1997-04-08 |
Isis Pharmacueticals, Inc. |
Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
|
|
US5223618A
(en)
|
1990-08-13 |
1993-06-29 |
Isis Pharmaceuticals, Inc. |
4'-desmethyl nucleoside analog compounds
|
|
US5608046A
(en)
|
1990-07-27 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Conjugated 4'-desmethyl nucleoside analog compounds
|
|
US6121433A
(en)
|
1990-07-27 |
2000-09-19 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds having nitrogen-containing linkages
|
|
US5998603A
(en)
|
1994-09-29 |
1999-12-07 |
Isis Pharmaceuticals, Inc. |
4'-desmethyl nucleoside analogs, and oligomers thereof
|
|
US5623070A
(en)
|
1990-07-27 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
|
US5378825A
(en)
|
1990-07-27 |
1995-01-03 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs
|
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
|
US5512668A
(en)
|
1991-03-06 |
1996-04-30 |
Polish Academy Of Sciences |
Solid phase oligonucleotide synthesis using phospholane intermediates
|
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
|
US20020183502A1
(en)
|
1991-05-21 |
2002-12-05 |
Mesmaeker Alain De |
Backbone-modified oligonucleotide analogs and methods for using same
|
|
US6414112B1
(en)
|
1991-05-24 |
2002-07-02 |
Ole Buchardt |
Peptide nucleic acids having 2,6-diaminopurine nucleobases
|
|
CA2111108A1
(en)
|
1991-06-10 |
1992-12-23 |
Joong Myung Cho |
Hepatitis c diagnostics and vaccines
|
|
US5646267A
(en)
|
1991-08-05 |
1997-07-08 |
Polish Academy Of Sciences |
Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
|
|
US5359052A
(en)
|
1991-08-05 |
1994-10-25 |
Polish Academy Of Sciences |
Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
|
|
US6369209B1
(en)
|
1999-05-03 |
2002-04-09 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having A-DNA form and B-DNA form conformational geometry
|
|
US7119184B2
(en)
|
1991-08-12 |
2006-10-10 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having A-DNA form and B-DNA form conformational geometry
|
|
US5599797A
(en)
|
1991-10-15 |
1997-02-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
|
US5661134A
(en)
|
1991-10-15 |
1997-08-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
|
|
US5576302A
(en)
|
1991-10-15 |
1996-11-19 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
|
|
US5607923A
(en)
|
1991-10-15 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
|
|
CA2121144C
(en)
*
|
1991-10-15 |
2001-07-31 |
Phillip Dan Cook |
Oligonucleotides having chiral phosphorus linkages
|
|
US5654284A
(en)
|
1991-10-15 |
1997-08-05 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
|
|
DE59208572D1
(de)
|
1991-10-17 |
1997-07-10 |
Ciba Geigy Ag |
Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
|
|
US5594121A
(en)
|
1991-11-07 |
1997-01-14 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
|
US5484908A
(en)
|
1991-11-26 |
1996-01-16 |
Gilead Sciences, Inc. |
Oligonucleotides containing 5-propynyl pyrimidines
|
|
US6235887B1
(en)
|
1991-11-26 |
2001-05-22 |
Isis Pharmaceuticals, Inc. |
Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
|
|
US5359044A
(en)
|
1991-12-13 |
1994-10-25 |
Isis Pharmaceuticals |
Cyclobutyl oligonucleotide surrogates
|
|
ATE317848T1
(de)
|
1991-12-24 |
2006-03-15 |
Isis Pharmaceuticals Inc |
Unterbrochene 2'-modifizierte oligonukleotide
|
|
GB9213601D0
(en)
|
1992-06-26 |
1992-08-12 |
Mastico Robert A |
Protein based delivery system
|
|
US7067497B2
(en)
|
1992-09-29 |
2006-06-27 |
Isis Pharmaceuticals, Inc. |
Modulation of telomere length by oligonucleotides having a G-core sequence
|
|
US6005107A
(en)
|
1992-12-23 |
1999-12-21 |
Biochem Pharma, Inc. |
Antiviral compounds
|
|
US6444656B1
(en)
|
1992-12-23 |
2002-09-03 |
Biochem Pharma, Inc. |
Antiviral phosphonate nucleotides
|
|
AU6165494A
(en)
|
1993-01-25 |
1994-08-15 |
Hybridon, Inc. |
Oligonucleotide alkylphosphonates and alkylphosphonothioates
|
|
AU6551094A
(en)
|
1993-03-31 |
1994-10-24 |
Sterling Winthrop Inc. |
Bifunctional nucleosides, oligomers thereof, and methods of making and using the same
|
|
EP0691979A1
(en)
|
1993-03-31 |
1996-01-17 |
Sanofi |
Novel 5'-substituted nucleosides and oligomers produced therefrom
|
|
US5955591A
(en)
|
1993-05-12 |
1999-09-21 |
Imbach; Jean-Louis |
Phosphotriester oligonucleotides, amidites and method of preparation
|
|
US6015886A
(en)
|
1993-05-24 |
2000-01-18 |
Chemgenes Corporation |
Oligonucleotide phosphate esters
|
|
EP0628394B1
(en)
|
1993-06-10 |
1998-08-26 |
Idemitsu Petrochemical Co. Ltd. |
Injection molding die
|
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
|
US5643989A
(en)
|
1993-10-29 |
1997-07-01 |
Azdel, Inc. |
Fiber reinforced functionalized polyolefin composites
|
|
US5457187A
(en)
|
1993-12-08 |
1995-10-10 |
Board Of Regents University Of Nebraska |
Oligonucleotides containing 5-fluorouracil
|
|
DE4435728A1
(de)
|
1994-01-19 |
1995-07-20 |
Boehringer Mannheim Gmbh |
Biotinsilan-Verbindungen und diese Verbindungen enthaltende Bindematrix
|
|
US6117679A
(en)
|
1994-02-17 |
2000-09-12 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
|
ATE222604T1
(de)
|
1994-02-22 |
2002-09-15 |
Novozymes As |
Methode zur herstellung einer variante eines lipolytischen enzymes
|
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
|
US5871966A
(en)
|
1994-05-11 |
1999-02-16 |
Novo Nordisk A/S |
Enzyme with endo-1,3(4)-β- Glucanase activity
|
|
US5525711A
(en)
|
1994-05-18 |
1996-06-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pteridine nucleotide analogs as fluorescent DNA probes
|
|
ES2127966T3
(es)
|
1994-05-31 |
1999-05-01 |
Bayer Ag |
Derivados de amino-benzofurilo y -benzotienilo.
|
|
HRP950288A2
(en)
|
1994-05-31 |
1997-08-31 |
Bayer Ag |
Oxalylamino-benzofuran- and benzothienyl-derivatives
|
|
CA2560114A1
(en)
|
1994-07-15 |
1996-02-01 |
The University Of Iowa Research Foundation |
Immunomodulatory oligonucleotides
|
|
US6239116B1
(en)
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
CA2199464A1
(en)
|
1994-09-07 |
1996-03-14 |
Radhakrishnan Iyer |
Oligonucleotide prodrugs
|
|
US5681940A
(en)
|
1994-11-02 |
1997-10-28 |
Icn Pharmaceuticals |
Sugar modified nucleosides and oligonucleotides
|
|
CN1175281A
(zh)
|
1994-12-22 |
1998-03-04 |
海布里登公司 |
立体特异性硫代磷酸寡核苷酸的合成
|
|
GB9501465D0
(en)
|
1995-01-25 |
1995-03-15 |
King S College London |
Nucleoside phosphorothioate derivatives,synthesis and use thereof
|
|
WO1996027606A1
(en)
|
1995-03-06 |
1996-09-12 |
Isis Pharmaceuticals, Inc. |
Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
|
|
US6166197A
(en)
|
1995-03-06 |
2000-12-26 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
|
|
DE69638104D1
(de)
|
1995-04-27 |
2010-02-11 |
Takara Bio Inc |
Für Lacto-N-biosidase kodierendes Gen
|
|
ES2220929T3
(es)
|
1995-05-11 |
2004-12-16 |
Applied Research Systems Ars Holding N.V. |
Inhibidor de la actividad il-6.
|
|
CA2221589A1
(en)
|
1995-05-19 |
1996-11-21 |
Glycomed Incorporated |
Collection of activated glycoside compounds and their biological use
|
|
AU5871196A
(en)
|
1995-05-23 |
1996-12-24 |
Hybridon, Inc. |
Methods and compounds for the synthesis of oligonucleotides and the oligonucleotides thereby produced
|
|
DK0836612T3
(da)
|
1995-05-23 |
2000-10-30 |
Hybridon Inc |
Nye synthoner til stereoselektiv oligonucleotidsyntese
|
|
EP0831854A4
(en)
|
1995-06-06 |
2001-01-24 |
Isis Pharmaceuticals Inc |
OLIGONUCLEOTIDS WITH PHOSPHOROTHIOATE BINDINGS OF HIGH CHIRAL PURITY
|
|
US5932450A
(en)
|
1995-06-07 |
1999-08-03 |
Gen-Probe Incorporated |
Enzymatic synthesis of oligonucleotides using digestible templates
|
|
EP0751222B1
(en)
|
1995-06-29 |
2006-03-01 |
Takara Bio Inc. |
Gene encoding endoglycoceramidase
|
|
DE69636649T2
(de)
|
1995-06-29 |
2007-10-04 |
Takara Bio Inc., Otsu |
Für einen Endoglycoceramidase-Aktivator kodierendes Gen
|
|
US6017700A
(en)
|
1995-08-04 |
2000-01-25 |
Bayer Corporation |
Cationic oligonucleotides, and related methods of synthesis and use
|
|
US5936080A
(en)
|
1996-05-24 |
1999-08-10 |
Genta Incorporated |
Compositions and methods for the synthesis of organophosphorus derivatives
|
|
WO1997009443A1
(en)
|
1995-09-05 |
1997-03-13 |
Michigan State University |
PROCESS FOR THE ISOLATION AND PURIFICATION OF TAXOL AND TAXANES FROM TAXUS spp
|
|
US6160109A
(en)
|
1995-10-20 |
2000-12-12 |
Isis Pharmaceuticals, Inc. |
Preparation of phosphorothioate and boranophosphate oligomers
|
|
US6476216B1
(en)
|
1995-10-20 |
2002-11-05 |
Mcgill University |
Preparation of phosphorothioate oligomers
|
|
US5734041A
(en)
|
1995-10-20 |
1998-03-31 |
Mcgill University |
Preparation of chiral phosphorothioate oligomers
|
|
US7018793B1
(en)
|
1995-12-07 |
2006-03-28 |
Diversa Corporation |
Combinatorial screening of mixed populations of organisms
|
|
US6214805B1
(en)
|
1996-02-15 |
2001-04-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
RNase L activators and antisense oligonucleotides effective to treat RSV infections
|
|
CN1215994A
(zh)
|
1996-02-15 |
1999-05-05 |
国家健康学会 |
对治疗rsv感染有效的rna酶l激活剂和反义寡核苷酸
|
|
GB9604669D0
(en)
|
1996-03-05 |
1996-05-01 |
Ciba Geigy Ag |
Chemical compounds
|
|
US5824669A
(en)
|
1996-03-22 |
1998-10-20 |
Nitromed, Inc. |
Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
|
|
EP0898618B1
(en)
|
1996-05-10 |
2007-10-31 |
Novozymes A/S |
Method of providing novel dna sequences
|
|
US5856465A
(en)
|
1996-05-24 |
1999-01-05 |
Polska Akademia Nauk Centrum Badan Molekularnych I Makromolekularnych |
Compositions and methods for the synthesis of chirally pure organophosphorus nucleoside derivatives
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
DE19622783A1
(de)
|
1996-06-07 |
1997-12-11 |
Hoechst Ag |
Isolierung der Biosynthesegene für Pseudo-Oligosaccharide aus Streptomyces glaucescens GLA.O und ihre Verwendung
|
|
EP0912767B1
(en)
|
1996-07-16 |
2006-09-13 |
Gen-Probe Incorporated |
Methods for detecting and amplifying nucleic acid sequences using modified oligonucleotides having increased target specific tm
|
|
CA2261566A1
(en)
|
1996-07-24 |
1998-01-29 |
Buchardt, Dorte |
Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
|
|
WO1998007734A1
(en)
|
1996-08-21 |
1998-02-26 |
Hybridon, Inc. |
Oligonucleotide prodrugs
|
|
US6056973A
(en)
|
1996-10-11 |
2000-05-02 |
Sequus Pharmaceuticals, Inc. |
Therapeutic liposome composition and method of preparation
|
|
GB9621522D0
(en)
|
1996-10-16 |
1996-12-04 |
Biocompatibles Ltd |
Synthesis of phosphorus compounds
|
|
US6639062B2
(en)
|
1997-02-14 |
2003-10-28 |
Isis Pharmaceuticals, Inc. |
Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
|
|
US6172209B1
(en)
|
1997-02-14 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Aminooxy-modified oligonucleotides and methods for making same
|
|
US6369237B1
(en)
|
1997-03-07 |
2002-04-09 |
President And Fellows Of Harvard College |
DNA glycosylase inhibitors, and uses related thereto
|
|
US6015887A
(en)
|
1997-04-11 |
2000-01-18 |
Isis Pharmaceuticals, Inc. |
Chiral peptide nucleic acids and methods for preparing same
|
|
US6468983B2
(en)
|
1997-04-21 |
2002-10-22 |
The Cleveland Clinic Foundation |
RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
|
|
PL184612B1
(pl)
|
1997-04-25 |
2002-11-29 |
Pan |
Sposób wytwarzania modyfikowanych P chiralnych analogów nukleotydów
|
|
EP1003480A4
(en)
|
1997-05-28 |
2002-04-17 |
Nielsen Peter Eigil |
NUCLEIC ACIDS CONJUGED WITH PEPTIDES WITH INCREASED UPDATE IN CELLS
|
|
JP2002507212A
(ja)
|
1997-06-27 |
2002-03-05 |
ザ、プロクター、エンド、ギャンブル、カンパニー |
プロ芳香性環状アセタール
|
|
AU8512598A
(en)
|
1997-07-25 |
1999-02-16 |
Hybridon, Inc. |
Oligonuclotides having 3' terminal stereospecific phosphorothioates
|
|
US6383808B1
(en)
|
2000-09-11 |
2002-05-07 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of clusterin expression
|
|
US6767739B2
(en)
|
2001-07-30 |
2004-07-27 |
Isis Pharmaceuticals Inc. |
Antisense modulation of microsomal triglyceride transfer protein expression
|
|
GB9717158D0
(en)
|
1997-08-13 |
1997-10-22 |
King S College London |
Solution synthesis of oligonucleotides and their phosphorothioate analogues
|
|
US6750344B1
(en)
|
1997-09-05 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Amine compounds and combinatorial libraries comprising same
|
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
|
DE19741715A1
(de)
|
1997-09-22 |
1999-03-25 |
Hoechst Ag |
Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung
|
|
US6232463B1
(en)
|
1997-10-09 |
2001-05-15 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
|
US6617438B1
(en)
|
1997-11-05 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Oligoribonucleotides with enzymatic activity
|
|
US6528640B1
(en)
|
1997-11-05 |
2003-03-04 |
Ribozyme Pharmaceuticals, Incorporated |
Synthetic ribonucleic acids with RNAse activity
|
|
US6080543A
(en)
|
1997-12-08 |
2000-06-27 |
E. & J. Gallo Winery |
Detection of fungal pathogens
|
|
US6582936B1
(en)
|
1997-12-12 |
2003-06-24 |
The Regents Of The University Of California |
Methods for making nucleic acids
|
|
US6248519B1
(en)
|
1998-03-11 |
2001-06-19 |
E & J Gallo Winery |
Detection of fermentation-related microorganisms
|
|
US7045610B2
(en)
|
1998-04-03 |
2006-05-16 |
Epoch Biosciences, Inc. |
Modified oligonucleotides for mismatch discrimination
|
|
CA2328602A1
(en)
|
1998-05-06 |
1999-11-11 |
University Of Iowa Research Foundation |
Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
|
|
DE69927495T2
(de)
|
1998-05-14 |
2006-07-06 |
Coley Pharmaceutical Group, Inc., Wellesley |
Verfahren zur regulieren der hämatopoese mit hilfe von cpg-oligonukleotiden
|
|
US6242589B1
(en)
|
1998-07-14 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Phosphorothioate oligonucleotides having modified internucleoside linkages
|
|
US6867294B1
(en)
|
1998-07-14 |
2005-03-15 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
|
WO2000006588A1
(en)
|
1998-07-27 |
2000-02-10 |
University Of Iowa Research Foundation |
STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS
|
|
WO2000009159A1
(en)
|
1998-08-10 |
2000-02-24 |
Aquila Biopharmaceuticals, Inc. |
Compositions of cpg and saponin adjuvants and methods thereof
|
|
WO2000023444A1
(en)
|
1998-10-21 |
2000-04-27 |
Abbott Laboratories |
5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
|
|
US6995259B1
(en)
|
1998-10-23 |
2006-02-07 |
Sirna Therapeutics, Inc. |
Method for the chemical synthesis of oligonucleotides
|
|
US6451524B1
(en)
|
1998-11-25 |
2002-09-17 |
Isis Pharmaceuticals, Inc. |
Identification of disease predictive nucleic acids
|
|
AU1742600A
(en)
|
1998-11-25 |
2000-06-13 |
Isis Pharmaceuticals, Inc. |
Identification of disease predictive nucleic acids
|
|
CA2359816C
(en)
|
1999-01-06 |
2010-08-03 |
Genenews Inc. |
Method for the detection of gene transcripts in blood and uses thereof
|
|
US6265172B1
(en)
|
1999-02-08 |
2001-07-24 |
University Of Kentucky |
Diagnostic test and therapy for manganese superoxide dismutate (mNsod) associated diseases
|
|
US6121437A
(en)
|
1999-03-16 |
2000-09-19 |
Isis Pharmaceuticals, Inc. |
Phosphate and thiophosphate protecting groups
|
|
US6506594B1
(en)
|
1999-03-19 |
2003-01-14 |
Cornell Res Foundation Inc |
Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
|
|
GB9907245D0
(en)
|
1999-03-29 |
1999-05-26 |
Goldsborough Andrew |
Cleavage of nucleic acids from solid supports
|
|
JP3072345B1
(ja)
|
1999-03-31 |
2000-07-31 |
農林水産省家畜衛生試験場長 |
豚丹毒菌の組換えサブユニットワクチン
|
|
US5998148A
(en)
|
1999-04-08 |
1999-12-07 |
Isis Pharmaceuticals Inc. |
Antisense modulation of microtubule-associated protein 4 expression
|
|
US6977245B2
(en)
|
1999-04-12 |
2005-12-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
|
US6300069B1
(en)
|
1999-05-03 |
2001-10-09 |
Qiagen Gmbh |
Generation and amplification of nucleic acids from ribonucleic acids
|
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
|
US6271004B1
(en)
|
1999-06-25 |
2001-08-07 |
Display Systems Biotech A/S |
Method for improved reverse transcription at high temperatures
|
|
US6066500A
(en)
|
1999-06-25 |
2000-05-23 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Beta catenin expression
|
|
US6414135B1
(en)
|
1999-07-07 |
2002-07-02 |
Isis Pharmaceuticals, Inc. |
C3′-methylene hydrogen phosphonate monomers and related compounds
|
|
US20030092647A1
(en)
|
2001-08-08 |
2003-05-15 |
Crooke Rosanne M. |
Antisense modulation of cholesteryl ester transfer protein expression
|
|
US6147200A
(en)
|
1999-08-19 |
2000-11-14 |
Isis Pharmaceuticals, Inc. |
2'-O-acetamido modified monomers and oligomers
|
|
US7264932B2
(en)
|
1999-09-24 |
2007-09-04 |
Applera Corporation |
Nuclease inhibitor cocktail
|
|
TR200200797T2
(tr)
|
1999-09-25 |
2002-10-21 |
University Of Iowa Research Foundation |
İmmünostimülatör nükleik asitler
|
|
US6949520B1
(en)
|
1999-09-27 |
2005-09-27 |
Coley Pharmaceutical Group, Inc. |
Methods related to immunostimulatory nucleic acid-induced interferon
|
|
NZ517928A
(en)
|
1999-09-27 |
2004-09-24 |
Coley Pharm Gmbh |
Methods related to immunostimulatory nucleic acid-induced interferon
|
|
US20020082227A1
(en)
|
1999-09-30 |
2002-06-27 |
Scott Henry |
Use of oligonucleotides for inhibition of complement activation
|
|
IL148922A0
(en)
|
1999-10-06 |
2002-09-12 |
Quark Biotech Inc |
Method for enrichment of natural antisense messenger rna
|
|
GB9924285D0
(en)
|
1999-10-14 |
1999-12-15 |
Avecia Ltd |
Process
|
|
US20010055761A1
(en)
|
1999-10-29 |
2001-12-27 |
Agilent Technologies |
Small scale dna synthesis using polymeric solid support with functionalized regions
|
|
FR2800750B1
(fr)
|
1999-11-05 |
2003-01-31 |
Centre Nat Rech Scient |
Proteines membranaires ctl (choline transporter like) impliquees dans le transport de la choline
|
|
AU1656601A
(en)
|
1999-11-12 |
2001-06-12 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
|
US6322985B1
(en)
|
1999-12-27 |
2001-11-27 |
Technion Research And Development Foundation Ltd. |
Abundant, well distributed and hyperpolymorphic simple sequence repeats in prokaryote genomes and use of same for prokaryote classification and typing
|
|
WO2001050349A1
(en)
|
1999-12-30 |
2001-07-12 |
Rutgers, The State University Of New Jersey |
Electronic document customization and transformation utilizing user feedback
|
|
EP1244906A1
(en)
|
1999-12-30 |
2002-10-02 |
Cabot Corporation |
Sensors with improved properties
|
|
US6649750B1
(en)
|
2000-01-05 |
2003-11-18 |
Isis Pharmaceuticals, Inc. |
Process for the preparation of oligonucleotide compounds
|
|
US6159697A
(en)
|
2000-01-19 |
2000-12-12 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of Smad7 expression
|
|
US7585847B2
(en)
|
2000-02-03 |
2009-09-08 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory nucleic acids for the treatment of asthma and allergy
|
|
US6495677B1
(en)
|
2000-02-15 |
2002-12-17 |
Kanda S. Ramasamy |
Nucleoside compounds
|
|
GB0004889D0
(en)
|
2000-03-01 |
2000-04-19 |
Avecia Ltd |
Synthesis of oligonucleotides
|
|
CA2335389A1
(en)
|
2000-03-01 |
2001-09-01 |
Message Pharmaceuticals, Inc. |
Novel bacterial rnase p proteins and their use in identifying antibacterial compounds
|
|
JP2003528068A
(ja)
|
2000-03-17 |
2003-09-24 |
コリクサ コーポレイション |
新規両親媒性アルデヒドならびにアジュバントおよび免疫エフェクターとしてのそれらの使用
|
|
AU7394201A
(en)
|
2000-04-20 |
2001-11-07 |
Hoffmann La Roche |
Pyrrolidine and piperidine derivatives and their use for the treament of neurodegenerative disorders
|
|
DE10019756A1
(de)
|
2000-04-20 |
2001-10-25 |
Bayer Ag |
Verfahren zur Herstellung von superabsorbierenden Polymeren aus Polyacrylnitrilen
|
|
WO2001085751A1
(en)
|
2000-05-09 |
2001-11-15 |
Reliable Biopharmaceutical, Inc. |
Polymeric compounds useful as prodrugs
|
|
US6492171B2
(en)
|
2000-05-16 |
2002-12-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of TERT expression
|
|
US6815542B2
(en)
|
2000-06-16 |
2004-11-09 |
Ribapharm, Inc. |
Nucleoside compounds and uses thereof
|
|
DE60132596T2
(de)
|
2000-08-03 |
2009-02-19 |
Roche Diagnostics Gmbh |
NUKLEINSÄUREBINDENDE VERBINDUNGEN MIT PYRAZOLOi3,4-D PYRIMIDINANALOGEN VON PURIN-2,6-DIAMIN UND IHRE VERWENDUNG
|
|
US6725412B1
(en)
|
2000-08-15 |
2004-04-20 |
Dolby Laboratories Licensing Corporation |
Low latency data encoder
|
|
US6809195B1
(en)
|
2000-08-16 |
2004-10-26 |
Isis Pharmaceuticals, Inc. |
Process for the preparation of oligonucleotides
|
|
US6559279B1
(en)
|
2000-09-08 |
2003-05-06 |
Isis Pharmaceuticals, Inc. |
Process for preparing peptide derivatized oligomeric compounds
|
|
CA2419894A1
(en)
|
2000-09-15 |
2002-03-21 |
Coley Pharmaceutical Gmbh |
Process for high throughput screening of cpg-based immuno-agonist/antagonist
|
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
|
GB0024752D0
(en)
|
2000-10-10 |
2000-11-22 |
Univ Belfast |
Oxidative halogenation of aromatic compounds
|
|
EP1326638B9
(en)
|
2000-10-18 |
2008-02-20 |
GlaxoSmithKline Biologicals S.A. |
Vaccines against cancers
|
|
US6372492B1
(en)
|
2000-10-30 |
2002-04-16 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of talin expression
|
|
US6682889B1
(en)
|
2000-11-08 |
2004-01-27 |
Becton, Dickinson And Company |
Amplification and detection of organisms of the Chlamydiaceae family
|
|
NL1016978C2
(nl)
|
2000-12-22 |
2002-06-25 |
Robert Jan Colenbrander |
Inrichting en werkwijze voor het verpakken en bereiden van voedsel en werkwijze voor het vervaardigen van een dergelijke inrichting.
|
|
NZ526703A
(en)
|
2001-01-22 |
2004-12-24 |
Merck & Co Inc |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
|
US8008459B2
(en)
|
2001-01-25 |
2011-08-30 |
Evolva Sa |
Concatemers of differentially expressed multiple genes
|
|
DK1356037T3
(da)
|
2001-01-25 |
2011-06-27 |
Evolva Ltd |
Bibliotek med en samling af celler
|
|
WO2002059294A1
(en)
|
2001-01-26 |
2002-08-01 |
Commonwealth Scientific And Industrial Research O Rganisation |
Methods and means for producing efficient silencing construct using recombinational cloning
|
|
US20050277133A1
(en)
|
2001-05-18 |
2005-12-15 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
|
US20030207804A1
(en)
|
2001-05-25 |
2003-11-06 |
Muthiah Manoharan |
Modified peptide nucleic acids
|
|
GB0113523D0
(en)
|
2001-06-04 |
2001-07-25 |
Torotrak Dev Ltd |
An Hydraulic control circuit for a continuosly variable transmission
|
|
US20030069410A1
(en)
*
|
2001-06-14 |
2003-04-10 |
Isis Pharmaceuticals, Inc. |
Methods for preparing oligonucleotides having chiral phosphorothioate linkages
|
|
US20050019915A1
(en)
|
2001-06-21 |
2005-01-27 |
Bennett C. Frank |
Antisense modulation of superoxide dismutase 1, soluble expression
|
|
CZ20033515A3
(cs)
|
2001-06-29 |
2005-01-12 |
Chiron Corporation |
Kompozice vakcíny HCV E1E2
|
|
JP2005504020A
(ja)
|
2001-07-03 |
2005-02-10 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
ヌクレアーゼ耐性キメラオリゴヌクレオチド
|
|
US7205399B1
(en)
|
2001-07-06 |
2007-04-17 |
Sirna Therapeutics, Inc. |
Methods and reagents for oligonucleotide synthesis
|
|
US6440739B1
(en)
|
2001-07-17 |
2002-08-27 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of glioma-associated oncogene-2 expression
|
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
|
US6455308B1
(en)
|
2001-08-01 |
2002-09-24 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of serum amyloid A4 expression
|
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
|
US7888324B2
(en)
|
2001-08-01 |
2011-02-15 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
|
US7259150B2
(en)
|
2001-08-07 |
2007-08-21 |
Isis Pharmaceuticals, Inc. |
Modulation of apolipoprotein (a) expression
|
|
AU2002361468A1
(en)
|
2001-08-14 |
2003-03-18 |
The Government Of The United States Of America As Represented By The Secretary Of Health And Human S |
Method for rapid generation of mature dendritic cells
|
|
EP1418877A2
(en)
|
2001-08-24 |
2004-05-19 |
Massachusetts Institute Of Technology |
Reagents that facilitate the purification of compounds synthesized on a solid support
|
|
US7049122B2
(en)
|
2001-09-21 |
2006-05-23 |
Academia Sinica |
Mutant-type lipases and applications thereof
|
|
US6933288B2
(en)
|
2002-02-04 |
2005-08-23 |
Isis Pharmaceuticals, Inc. |
Pyranosyl cytosines: pharmaceutical formulations and methods
|
|
JP4348044B2
(ja)
|
2002-02-12 |
2009-10-21 |
株式会社キラルジェン |
立体規則性の高いジヌクレオシドホスホロチオエートの製造法
|
|
US20030159938A1
(en)
|
2002-02-15 |
2003-08-28 |
George Hradil |
Electroplating solution containing organic acid complexing agent
|
|
US20040149587A1
(en)
|
2002-02-15 |
2004-08-05 |
George Hradil |
Electroplating solution containing organic acid complexing agent
|
|
US20050096284A1
(en)
|
2002-02-20 |
2005-05-05 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
|
US8232383B2
(en)
|
2002-02-20 |
2012-07-31 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
WO2003073989A2
(en)
|
2002-02-28 |
2003-09-12 |
Biota, Inc. |
Nucleoside 5'-monophosphate mimics and their prodrugs
|
|
WO2003072757A2
(en)
|
2002-02-28 |
2003-09-04 |
Biota, Inc. |
Nucleotide mimics and their prodrugs
|
|
US7288376B2
(en)
|
2002-03-22 |
2007-10-30 |
Council Of Scientific And Industrial Research |
Method of detection of SP-A2 gene variants useful for prediction of predisposition to aspergillosis
|
|
US20040102394A1
(en)
|
2002-11-23 |
2004-05-27 |
Isis Pharmaceuticals Inc. |
Modulation of huntingtin interacting protein 2 expression
|
|
US7247621B2
(en)
|
2002-04-30 |
2007-07-24 |
Valeant Research & Development |
Antiviral phosphonate compounds and methods therefor
|
|
AU2003237875A1
(en)
|
2002-05-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein b expression
|
|
AU2003241621A1
(en)
|
2002-05-24 |
2003-12-12 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having modified nucleoside units
|
|
US20040014957A1
(en)
|
2002-05-24 |
2004-01-22 |
Anne Eldrup |
Oligonucleotides having modified nucleoside units
|
|
US7507808B2
(en)
|
2002-12-12 |
2009-03-24 |
Isis Pharmaceuticals, Inc. |
Modulation of endothelial lipase expression
|
|
AU2003248708A1
(en)
|
2002-06-17 |
2003-12-31 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
|
|
DE60335186D1
(de)
|
2002-06-20 |
2011-01-13 |
Cytos Biotechnology Ag |
Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
|
|
WO2004003228A1
(en)
|
2002-07-01 |
2004-01-08 |
Unisearch Limited |
Genotyping method
|
|
CA2489174C
(en)
|
2002-07-10 |
2013-02-05 |
Thomas Tuschl |
Rna-interference by single-stranded rna molecules
|
|
US20040023905A1
(en)
|
2002-07-31 |
2004-02-05 |
Isis Pharmaceuticals Inc. |
Antisense modulation of LAR expression
|
|
US20050042646A1
(en)
|
2002-08-05 |
2005-02-24 |
Davidson Beverly L. |
RNA interference suppresion of neurodegenerative diseases and methods of use thereof
|
|
US20080274989A1
(en)
|
2002-08-05 |
2008-11-06 |
University Of Iowa Research Foundation |
Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
|
|
US20050255086A1
(en)
|
2002-08-05 |
2005-11-17 |
Davidson Beverly L |
Nucleic acid silencing of Huntington's Disease gene
|
|
WO2004014933A1
(en)
|
2002-08-07 |
2004-02-19 |
University Of Massachusetts |
Compositions for rna interference and methods of use thereof
|
|
AU2003259735A1
(en)
|
2002-08-08 |
2004-02-25 |
Sirna Therapeutics, Inc. |
Small-mer compositions and methods of use
|
|
AR040996A1
(es)
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
|
US7414116B2
(en)
|
2002-08-23 |
2008-08-19 |
Illumina Cambridge Limited |
Labelled nucleotides
|
|
CA2498777C
(en)
|
2002-09-13 |
2015-01-13 |
Replicor, Inc. |
Non-sequence complementary antiviral oligonucleotides
|
|
US7030230B2
(en)
|
2002-10-25 |
2006-04-18 |
Isis Pharmaceuticals, Inc. |
Process of purifying phosphoramidites
|
|
BR0315810A
(pt)
|
2002-10-29 |
2005-09-13 |
Coley Pharmaceutical Group Ltd |
Uso de oligonucleotìdeos cpg no tratamento de infecção por vìrus da hepatite c
|
|
EP2957568B1
(en)
|
2002-11-05 |
2016-12-21 |
Ionis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
|
WO2004044134A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Phosphorous-linked oligomeric compounds and their use in gene modulation
|
|
CA2505090A1
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Conjugated oligomeric compounds and their use in gene modulation
|
|
EP1562971B1
(en)
|
2002-11-05 |
2014-02-12 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
|
US7381527B2
(en)
|
2002-11-06 |
2008-06-03 |
Council Of Scientific And Industrial Research |
Method of detection of SP-A2 gene variants
|
|
WO2004044181A2
(en)
|
2002-11-13 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein b expression
|
|
US7511131B2
(en)
|
2002-11-13 |
2009-03-31 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
|
EP2213738B1
(en)
|
2002-11-14 |
2012-10-10 |
Dharmacon, Inc. |
siRNA molecules targeting Bcl-2
|
|
AU2003225705A1
(en)
|
2003-03-07 |
2004-09-30 |
Ribapharm Inc. |
Cytidine analogs and methods of use
|
|
CA2518475C
(en)
|
2003-03-07 |
2014-12-23 |
Alnylam Pharmaceuticals, Inc. |
Irna agents comprising asymmetrical modifications
|
|
CA2524255C
(en)
|
2003-03-21 |
2014-02-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
GB0306657D0
(en)
|
2003-03-24 |
2003-04-30 |
Avecia Ltd |
Process and compounds
|
|
US7517520B2
(en)
|
2003-03-26 |
2009-04-14 |
Cytos Biotechnology Ag |
Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
|
|
US7537767B2
(en)
|
2003-03-26 |
2009-05-26 |
Cytis Biotechnology Ag |
Melan-A- carrier conjugates
|
|
ITRM20030149A1
(it)
|
2003-04-02 |
2004-10-03 |
Giuliani Spa |
Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
|
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
|
WO2005002626A2
(en)
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
|
WO2004096233A2
(en)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Nucleoside phosphonate conjugates
|
|
US7432261B2
(en)
|
2003-04-25 |
2008-10-07 |
Gilead Sciences, Inc. |
Anti-inflammatory phosphonate compounds
|
|
CN101410120A
(zh)
|
2003-04-25 |
2009-04-15 |
吉里德科学公司 |
抗炎的膦酸酯化合物
|
|
US20090247488A1
(en)
|
2003-04-25 |
2009-10-01 |
Carina Cannizzaro |
Anti-inflammatory phosphonate compounds
|
|
US20050261237A1
(en)
|
2003-04-25 |
2005-11-24 |
Boojamra Constantine G |
Nucleoside phosphonate analogs
|
|
US7407965B2
(en)
|
2003-04-25 |
2008-08-05 |
Gilead Sciences, Inc. |
Phosphonate analogs for treating metabolic diseases
|
|
PT1628685E
(pt)
|
2003-04-25 |
2011-03-16 |
Gilead Sciences Inc |
Análogos de fosfonatos antivirais
|
|
WO2004096235A2
(en)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
|
US7470724B2
(en)
|
2003-04-25 |
2008-12-30 |
Gilead Sciences, Inc. |
Phosphonate compounds having immuno-modulatory activity
|
|
US7452901B2
(en)
|
2003-04-25 |
2008-11-18 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
|
US7045306B2
(en)
|
2003-04-28 |
2006-05-16 |
The General Hospital Corporation |
Method for identifying compounds in vitro that modulate the dysregulation of transcription of transcription mediated by mutant huntingtin protein
|
|
US7214491B2
(en)
|
2003-05-07 |
2007-05-08 |
E. I. Du Pont De Nemours And Company |
Δ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts
|
|
CA2526893C
(en)
|
2003-05-14 |
2010-10-26 |
Japan Science And Technology Agency |
Inhibition of the expression of huntingtin gene
|
|
EP2241572A3
(en)
|
2003-06-03 |
2011-04-06 |
Eli Lilly And Company |
Modulation of survivin expression
|
|
CA2528774A1
(en)
|
2003-06-20 |
2005-01-27 |
Coley Pharmaceutical Gmbh |
Small molecule toll-like receptor (tlr) antagonists
|
|
EP2530157B1
(en)
|
2003-07-31 |
2016-09-28 |
Regulus Therapeutics Inc. |
Oligomeric compounds and compositions for use in modulation of miRNAs
|
|
JP2011088935A
(ja)
|
2003-08-08 |
2011-05-06 |
Chiralgen Ltd |
リン原子修飾ヌクレオチド類縁体の製造のための光学活性ヌクレオシド３’−ホスホロアミダイト
|
|
JP2005089441A
(ja)
|
2003-08-08 |
2005-04-07 |
Toudai Tlo Ltd |
立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法
|
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
|
CA2535800A1
(en)
|
2003-08-21 |
2005-03-03 |
Griffith University |
Novel sulfenamide oxides
|
|
EP1664072A1
(en)
|
2003-08-21 |
2006-06-07 |
Griffith University |
Novel sulfenamides
|
|
RU2006109491A
(ru)
|
2003-08-27 |
2006-08-10 |
Байота, Инк. (Au) |
Новые трициклические нуклеозиды или нуклеотиды в качестве терапевтических средств
|
|
EP1661905B9
(en)
|
2003-08-28 |
2012-12-19 |
IMANISHI, Takeshi |
Novel artificial nucleic acids of n-o bond crosslinkage type
|
|
WO2005023828A1
(ja)
|
2003-09-02 |
2005-03-17 |
Takeshi Wada |
リボヌクレオチド又はリボヌクレオチド誘導体の製造方法
|
|
JP4616175B2
(ja)
|
2003-09-02 |
2011-01-19 |
株式会社キラルジェン |
５’−ホスフィチル化モノマーおよびｈ−ホスホネートオリゴヌクレオチド誘導体の製造方法
|
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
|
US20050074801A1
(en)
|
2003-09-09 |
2005-04-07 |
Monia Brett P. |
Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
|
|
SI1667522T1
(en)
|
2003-09-09 |
2018-04-30 |
Geron Corporation |
Modified oligonucleotides for the inhibition of telomerase
|
|
ES2969371T3
(es)
|
2003-09-12 |
2024-05-17 |
Univ Massachusetts |
Interferencia por ARN para el tratamiento de trastornos de ganancia de función
|
|
US8680063B2
(en)
|
2003-09-12 |
2014-03-25 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
|
GB0323968D0
(en)
|
2003-10-13 |
2003-11-19 |
Glaxosmithkline Biolog Sa |
Immunogenic compositions
|
|
NZ546275A
(en)
|
2003-10-30 |
2009-05-31 |
Coley Pharm Gmbh |
C-class oligonucleotides analogs with enhanced immunostimulatory potency
|
|
US20050239102A1
(en)
|
2003-10-31 |
2005-10-27 |
Verdine Gregory L |
Nucleic acid binding oligonucleotides
|
|
US7846436B2
(en)
|
2003-11-28 |
2010-12-07 |
Chemgenes Corporation |
Oligonucleotides and related compounds
|
|
WO2005063983A1
(en)
|
2003-12-29 |
2005-07-14 |
Galapagos Genomics N.V. |
Modulators of bone homeostasis identified in a high-throughput screen
|
|
WO2005070859A1
(ja)
|
2004-01-27 |
2005-08-04 |
Takeshi Wada |
フルオラス担体およびそれを用いたオリゴヌクレオチド誘導体の製造方法
|
|
US20050176045A1
(en)
|
2004-02-06 |
2005-08-11 |
Dharmacon, Inc. |
SNP discriminatory siRNA
|
|
US20080221303A1
(en)
|
2004-02-18 |
2008-09-11 |
Jehoshua Katzhendler |
Method for the Preparation of Peptide-Oligonucleotide Conjugates
|
|
JP3976742B2
(ja)
|
2004-02-27 |
2007-09-19 |
江守商事株式会社 |
インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
|
|
WO2005085272A1
(ja)
|
2004-03-05 |
2005-09-15 |
Takeshi Wada |
ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法
|
|
WO2005092909A1
(ja)
|
2004-03-25 |
2005-10-06 |
Toudai Tlo, Ltd. |
立体規則性の高いリボヌクレオチド類縁体及びデオキシリボヌクレオチド類縁体の製造法
|
|
US20050244869A1
(en)
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
|
EP1737878A2
(en)
|
2004-04-05 |
2007-01-03 |
Alnylam Pharmaceuticals Inc. |
Process and reagents for oligonucleotide synthesis and purification
|
|
TWI350168B
(en)
|
2004-05-07 |
2011-10-11 |
Incyte Corp |
Amido compounds and their use as pharmaceuticals
|
|
WO2005116268A2
(en)
|
2004-05-27 |
2005-12-08 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health |
Differential expression of molecules associated with acute stroke
|
|
US7759318B1
(en)
|
2004-05-28 |
2010-07-20 |
Isis Pharmaceuticals, Inc. |
Identification of novel pathways, genes and promoter motifs regulating adipogenesis
|
|
EP1766071A4
(en)
|
2004-06-03 |
2009-11-11 |
Isis Pharmaceuticals Inc |
DOUBLE-STRONG COMPOSITIONS WITH DIFFERENTLY MODIFIED STRANDS FOR USE IN GENE MODULATION
|
|
EP1766010B1
(en)
|
2004-06-28 |
2011-02-16 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
|
WO2006020676A2
(en)
|
2004-08-10 |
2006-02-23 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein b expression
|
|
JP5157168B2
(ja)
|
2004-08-26 |
2013-03-06 |
日本新薬株式会社 |
ホスホロアミダイト化合物及びオリゴｒｎａの製法
|
|
EP1791557A4
(en)
|
2004-09-07 |
2009-09-23 |
Archemix Corp |
MEDICAL CHEMISTRY USING APTAMERS
|
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
|
US20090203132A1
(en)
|
2004-09-09 |
2009-08-13 |
Swayze Eric E |
Pyrrolidinyl groups for attaching conjugates to oligomeric compounds
|
|
EP2397563A3
(en)
|
2004-09-17 |
2012-07-18 |
Isis Pharmaceuticals, Inc. |
Enhanced antisense oligonucleotides
|
|
US20090036355A1
(en)
|
2004-10-13 |
2009-02-05 |
Sanjay Bhanot |
Antisense Modulation of PTP1B Expression
|
|
US7622451B2
(en)
|
2004-11-03 |
2009-11-24 |
University Of Kansas |
Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
|
|
US8212011B2
(en)
|
2004-11-03 |
2012-07-03 |
University Of Kansas |
Novobiocin analogues
|
|
AU2005301957B2
(en)
|
2004-11-03 |
2012-02-23 |
Department Of Health And Human Services |
Novobiocin analogues as anticancer agents
|
|
US9120774B2
(en)
|
2004-11-03 |
2015-09-01 |
University Of Kansas |
Novobiocin analogues having modified sugar moieties
|
|
US8212012B2
(en)
|
2004-11-03 |
2012-07-03 |
University Of Kansas |
Novobiocin analogues having modified sugar moieties
|
|
KR100721928B1
(ko)
|
2004-11-05 |
2007-05-28 |
주식회사 바이오씨에스 |
ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
|
|
EP1657307A1
(en)
|
2004-11-16 |
2006-05-17 |
Immunotech S.A. |
Oligonucleotides that induce the secretion of GM-CSF
|
|
AU2005313883B2
(en)
|
2004-12-09 |
2011-03-31 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
|
|
US9809824B2
(en)
|
2004-12-13 |
2017-11-07 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
|
|
WO2006066260A2
(en)
|
2004-12-17 |
2006-06-22 |
Thiosense, Inc. |
Compositions of and methods for producing phosphorus-chiral monomers and oligomers
|
|
US20070099851A1
(en)
|
2004-12-30 |
2007-05-03 |
Linn Gregory S |
Stable analogues of ribose-1-phosphate and methods for treating diabetes and other metabolic disorders
|
|
US20060183763A1
(en)
|
2004-12-31 |
2006-08-17 |
Pfizer Inc |
Novel pyrrolidyl derivatives of heteroaromatic compounds
|
|
CA2549423C
(en)
|
2005-01-28 |
2012-10-02 |
Hyung-Joo Kwon |
Oligonucleotides derived from mycobacterium for stimulating immune function, treating immune-related diseases, atopic dermatitis and/or protecting normal immune cell
|
|
CA2598992A1
(en)
|
2005-02-24 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory oligonucleotides
|
|
WO2006137953A1
(en)
|
2005-04-01 |
2006-12-28 |
The Regents Of The Univerisity Of California |
Phosphono-pent-2-en-1-yl nucleosides and analogs
|
|
NZ562954A
(en)
|
2005-05-05 |
2009-10-30 |
Antisense Pharma Gmbh |
Use of low doses of oligonucleotides antisense to TGF-beta, VEGF, interleukin-10, C-JUN, C-FOS or prostaglandin E2 genes in the treatment of tumors
|
|
EP1885854B1
(en)
|
2005-05-06 |
2012-10-17 |
Medtronic, Inc. |
Methods and sequences to suppress primate huntington gene expression
|
|
US7902352B2
(en)
|
2005-05-06 |
2011-03-08 |
Medtronic, Inc. |
Isolated nucleic acid duplex for reducing huntington gene expression
|
|
HUE027486T2
(en)
|
2005-06-23 |
2016-09-28 |
Isis Pharmaceuticals Inc |
Preparations and methods for modifying SMN2-Splicing
|
|
US9133517B2
(en)
|
2005-06-28 |
2015-09-15 |
Medtronics, Inc. |
Methods and sequences to preferentially suppress expression of mutated huntingtin
|
|
EP2062980B1
(en)
|
2005-06-28 |
2011-08-31 |
Medtronic, Inc. |
Methods and sequences to preferentially suppress expression of mutated huntingtin gene.
|
|
US20090162316A1
(en)
|
2005-07-05 |
2009-06-25 |
Harvard University |
Liver targeted conjugates
|
|
JP4984634B2
(ja)
|
2005-07-21 |
2012-07-25 |
ソニー株式会社 |
物理情報取得方法および物理情報取得装置
|
|
WO2007016379A2
(en)
|
2005-07-28 |
2007-02-08 |
Id-Fish Technology, Inc. |
Method for improving cell permeability to foreign particles
|
|
CA2620856C
(en)
|
2005-08-29 |
2017-11-28 |
Isis Pharmaceuticals, Inc. |
Methods for use in modulating mir-122a
|
|
US8501703B2
(en)
|
2005-08-30 |
2013-08-06 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds for modulation of splicing
|
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
|
US20070077993A1
(en)
|
2005-09-30 |
2007-04-05 |
Midgley Timothy M |
Method and apparatus for collecting user game play data and crediting users in a gaming environment
|
|
ES2542989T3
(es)
|
2005-10-12 |
2015-08-13 |
Idera Pharmaceuticals, Inc. |
Compuestos oligonucleótidos inmuno reguladores (IRO) para modular la respuesta inmune basada en receptor semejante a Toll
|
|
US9308252B2
(en)
|
2005-10-27 |
2016-04-12 |
Cook Biotech, Inc. |
Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
|
|
CA2627025A1
(en)
|
2005-10-28 |
2007-05-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of huntingtin gene
|
|
CN101466834B
(zh)
|
2005-10-28 |
2013-09-25 |
东曹株式会社 |
制备类胡萝卜素合成性微生物的方法和生产类胡萝卜素的方法
|
|
EP1963502A4
(en)
|
2005-11-11 |
2010-04-07 |
Pfizer |
COMBINATIONS AND METHOD FOR USE OF AN IMMUNOMODULATIVE OLIGODESOXYNUCLEOTIDE
|
|
WO2007064291A1
(en)
|
2005-11-30 |
2007-06-07 |
Jyoti Chattopadhyaya |
Method and compounds for rna synthesis
|
|
EP1957507B1
(en)
|
2005-12-02 |
2018-10-24 |
Ionis Pharmaceuticals, Inc. |
Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
|
|
US8076303B2
(en)
|
2005-12-13 |
2011-12-13 |
Spring Bank Pharmaceuticals, Inc. |
Nucleotide and oligonucleotide prodrugs
|
|
CA2634381C
(en)
|
2005-12-21 |
2011-03-08 |
Pfizer Products Inc. |
Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
|
|
ES2453380T3
(es)
|
2006-01-26 |
2014-04-07 |
Isis Pharmaceuticals, Inc. |
Composiciones y utilizaciones dirigidas hacia la huntingtina
|
|
PL2314594T3
(pl)
|
2006-01-27 |
2014-12-31 |
Isis Pharmaceuticals Inc |
Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych
|
|
US20080045473A1
(en)
|
2006-02-15 |
2008-02-21 |
Coley Pharmaceutical Gmbh |
Compositions and methods for oligonucleotide formulations
|
|
JP4713514B2
(ja)
|
2006-02-20 |
2011-06-29 |
エフ．ホフマン−ラ ロシュ アーゲー |
改善された標識試薬
|
|
US8383660B2
(en)
|
2006-03-10 |
2013-02-26 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
|
CN101454315B
(zh)
|
2006-03-31 |
2016-08-17 |
应用生物系统有限责任公司 |
用于合成罗丹明-标记的寡核苷酸的试剂
|
|
WO2007118222A2
(en)
|
2006-04-06 |
2007-10-18 |
Ibis Biosciences, INC |
Compositions for the use in identification of fungi
|
|
WO2007122103A1
(en)
|
2006-04-20 |
2007-11-01 |
F. Hoffmann-La Roche Ag |
Diazepan derivatives modulators of chemokine receptors
|
|
US8206923B2
(en)
|
2006-04-24 |
2012-06-26 |
Elvira Garza Gonzalez |
Method for detection and multiple, simultaneous quantification of pathogens by means of real-time polymerase chain reaction
|
|
AU2007243412A1
(en)
|
2006-04-25 |
2007-11-08 |
Immune Disease Institute Inc. |
Targeted delivery to leukocytes using non-protein carriers
|
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
|
WO2007131232A2
(en)
|
2006-05-05 |
2007-11-15 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to ptpr alpha
|
|
EP2397551A1
(en)
|
2006-05-05 |
2011-12-21 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of PCSK9
|
|
US20090012120A1
(en)
|
2006-05-10 |
2009-01-08 |
Board Of Trustees Of Michigan State University |
Synthesis of N-heterocycles, beta-amino acids, and allyl amines via aza-payne mediated reaction of ylides and hydroxy aziridines
|
|
WO2007134181A2
(en)
|
2006-05-11 |
2007-11-22 |
Isis Pharmaceuticals, Inc. |
5'-modified bicyclic nucleic acid analogs
|
|
US7666854B2
(en)
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
|
EP2034015B1
(en)
|
2006-05-31 |
2012-07-11 |
Toray Industries, Inc. |
Immunostimulatory oligonucleotide and pharmaceutical application thereof
|
|
US8097596B2
(en)
|
2006-06-30 |
2012-01-17 |
Lakewood-Amedex, Inc. |
Compositions and methods for the treatment of muscle wasting
|
|
CA2662704A1
(en)
|
2006-07-07 |
2008-01-10 |
University Of Massachusetts |
Rna silencing compositions and methods for the treatment of huntington's disease
|
|
AU2007272906B2
(en)
|
2006-07-12 |
2013-01-31 |
The Regents Of The University Of California |
Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups
|
|
AU2007275301A1
(en)
|
2006-07-20 |
2008-01-24 |
Amgen Inc. |
Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
|
|
GB0614947D0
(en)
|
2006-07-27 |
2006-09-06 |
Isis Innovation |
Epitope reduction therapy
|
|
JP2010500290A
(ja)
|
2006-08-04 |
2010-01-07 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
Ｊｎｋタンパク質を調節するための組成物および方法
|
|
AT504194B1
(de)
|
2006-09-07 |
2008-07-15 |
Oesterr Rotes Kreuz |
Bakteriennachweis
|
|
US8138330B2
(en)
|
2006-09-11 |
2012-03-20 |
Sigma-Aldrich Co. Llc |
Process for the synthesis of oligonucleotides
|
|
CN101517082B
(zh)
|
2006-09-27 |
2014-01-22 |
科勒制药有限责任公司 |
具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物
|
|
AU2007310989B2
(en)
|
2006-10-18 |
2014-05-29 |
Isis Pharmaceuticals, Inc. |
Antisense compounds
|
|
BRPI0717348A2
(pt)
|
2006-10-23 |
2013-10-15 |
Irm Llc |
Composições e processos para inibir captecina proteases
|
|
BRPI0718182A2
(pt)
|
2006-10-26 |
2014-02-25 |
Coley Pharm Gmbh |
Oligorribonucleotídeos e seus usos.
|
|
FR2908414B1
(fr)
|
2006-11-13 |
2012-01-20 |
Centre Nat Rech Scient |
Immobilisation de proteines membranaires sur un support par l'intermediaire d'une molecule amphiphile
|
|
WO2008060621A2
(en)
|
2006-11-17 |
2008-05-22 |
Abbott Laboratories |
Aminopyrrolidines as chemokine receptor antagonists
|
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
|
JP2010510807A
(ja)
|
2006-11-27 |
2010-04-08 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
高コレステロール血症を治療するための方法
|
|
US7884197B2
(en)
|
2006-12-12 |
2011-02-08 |
Idera Pharmaceuticals, Inc. |
Synthetic agonists of TLR9
|
|
UY30892A1
(es)
|
2007-02-07 |
2008-09-02 |
Smithkline Beckman Corp |
Inhibidores de la actividad akt
|
|
EP2125852B1
(en)
|
2007-02-15 |
2016-04-06 |
Ionis Pharmaceuticals, Inc. |
5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
|
|
BRPI0809320A2
(pt)
|
2007-03-24 |
2014-09-23 |
Genzyme Corp |
Método
|
|
US7960353B2
(en)
|
2007-05-10 |
2011-06-14 |
University Of Kansas |
Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
|
|
PT2158316E
(pt)
|
2007-05-11 |
2015-07-20 |
Adynxx Inc |
Expressão génica e dor
|
|
CA2688008A1
(en)
|
2007-05-24 |
2008-11-27 |
Kyorin Pharmaceutical Co., Ltd. |
Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position
|
|
GB0710186D0
(en)
|
2007-05-29 |
2007-07-04 |
Texas Instr Denmark |
PWM loop with minimum allasing error property
|
|
CA2688321A1
(en)
|
2007-05-30 |
2008-12-11 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
|
CN101808987A
(zh)
|
2007-06-05 |
2010-08-18 |
Nsab神经研究瑞典公司分公司 |
作为皮层儿茶酚胺能神经传递调节剂的二取代的苯基吡咯烷
|
|
ES2386492T3
(es)
|
2007-06-08 |
2012-08-21 |
Isis Pharmaceuticals, Inc. |
Análogos de ácidos nucleicos bicíclicos carbocíclicos
|
|
EP2164865A2
(en)
|
2007-06-13 |
2010-03-24 |
Hochschule Mannheim |
Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds
|
|
EP2014769B1
(en)
|
2007-06-18 |
2010-03-31 |
Commissariat à l'Energie Atomique |
Reversible siRNAa-based silencing of mutated and endogenous wild-type huntingtin gene and its application for the treatment of Huntington's disease
|
|
GB0712494D0
(en)
|
2007-06-27 |
2007-08-08 |
Isis Innovation |
Substrate reduction therapy
|
|
ATE538127T1
(de)
|
2007-07-05 |
2012-01-15 |
Isis Pharmaceuticals Inc |
6-disubstituierte bicyclische nukleinsäureanaloga
|
|
CN102921003B
(zh)
|
2007-07-09 |
2014-11-26 |
艾德拉药物股份有限公司 |
稳定化免疫调控性rna(simra)化合物
|
|
TWI413530B
(zh)
|
2007-07-20 |
2013-11-01 |
Kao Corp |
有機聚矽氧
|
|
WO2009015479A1
(en)
|
2007-07-31 |
2009-02-05 |
University Of Saskatchewan |
Genetic variation in pro-melanin-concentrating hormone gene affects carcass traits in cattle
|
|
US7812003B2
(en)
|
2007-08-02 |
2010-10-12 |
Safe Stephen H |
Antisense microRNA and uses therefor
|
|
WO2009023819A2
(en)
|
2007-08-15 |
2009-02-19 |
Idera Pharmaceuticals, Inc. |
Toll like receptor modulators
|
|
KR101660989B1
(ko)
|
2007-10-01 |
2016-09-28 |
아이오니스 파마수티컬즈, 인코포레이티드 |
섬유아세포 성장 인자 수용체 4 발현의 안티센스 조절
|
|
KR100886139B1
(ko)
|
2007-11-13 |
2009-02-27 |
주식회사 삼천리제약 |
올리고뉴클레오타이드의 제조방법
|
|
TW200930375A
(en)
|
2007-12-21 |
2009-07-16 |
Exelixis Inc |
Benzofuropyrimidinones
|
|
TWI340765B
(en)
|
2007-12-26 |
2011-04-21 |
Ind Tech Res Inst |
Oligonucleotide sequences and dna chip for identifying filamentous microorganisms and the identification method thereof
|
|
US20100309376A1
(en)
|
2008-01-15 |
2010-12-09 |
Yungchun Lei |
Multimedia Presenting System, Multimedia Processing Apparatus Thereof, and Method for Presenting Video and Audio Signals
|
|
WO2009089659A1
(en)
|
2008-01-18 |
2009-07-23 |
Shanghai Targetdrug Co., Ltd. |
Pyrollidine-based compounds
|
|
EP2240768A1
(en)
|
2008-02-04 |
2010-10-20 |
Galapagos N.V. |
Target sequences and methods to identify the same, useful in treatment of neurodegenerative diseases
|
|
JP2009190983A
(ja)
|
2008-02-12 |
2009-08-27 |
Tokyo Institute Of Technology |
オリゴヌクレオチド誘導体
|
|
EP2282744B1
(en)
|
2008-03-21 |
2018-01-17 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising tricyclic nucleosides and methods for their use
|
|
US20110269814A1
(en)
|
2008-03-26 |
2011-11-03 |
Alnylam Pharamaceuticals, Inc. |
2'-f modified rna interference agents
|
|
CN107753499A
(zh)
|
2008-04-03 |
2018-03-06 |
春堤制药公司 |
用于治疗病毒感染的化合物和方法
|
|
DE112009001327A5
(de)
|
2008-04-04 |
2011-03-31 |
Universität Hamburg |
Verfahren zur stereoselektiven Synthese von Phosphor-Verbindungen
|
|
EP2285819B1
(en)
|
2008-04-04 |
2013-10-16 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
|
|
EP2297341A4
(en)
|
2008-05-09 |
2013-01-09 |
Univ British Columbia |
METHOD AND COMPOSITIONS FOR TREATING MORBUS HUNTINGTON
|
|
US8679750B2
(en)
|
2008-05-09 |
2014-03-25 |
The University Of British Columbia |
Methods and compositions for the treatment of Huntington'S disease
|
|
WO2009143391A2
(en)
|
2008-05-22 |
2009-11-26 |
Isis Pharmaceuticals, Inc |
Methods for modulation expression of creb
|
|
WO2009143387A2
(en)
|
2008-05-22 |
2009-11-26 |
Isis Pharmaceuticals, Inc. |
Modulation of smrt expression
|
|
US8541388B2
(en)
|
2008-05-22 |
2013-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating expression of RBP4
|
|
WO2009148605A2
(en)
|
2008-06-04 |
2009-12-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
|
WO2010003133A2
(en)
|
2008-07-03 |
2010-01-07 |
Exelixis Inc. |
Cdk modulators
|
|
US8410070B2
(en)
|
2008-09-12 |
2013-04-02 |
University Of Louisville Research Foundation, Inc. |
Compositions and methods for treating cancer, inhibiting proliferation, and inducing cell death
|
|
WO2010030858A1
(en)
|
2008-09-15 |
2010-03-18 |
Enanta Pharmaceuticals, Inc. |
4'-allene-substituted nucleoside derivatives
|
|
WO2010039543A2
(en)
|
2008-09-23 |
2010-04-08 |
Traversa Therapeutics, Inc. |
Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
|
|
WO2010036698A1
(en)
|
2008-09-24 |
2010-04-01 |
Isis Pharmaceuticals, Inc. |
Substituted alpha-l-bicyclic nucleosides
|
|
DK2361256T3
(da)
|
2008-09-24 |
2013-07-01 |
Isis Pharmaceuticals Inc |
Cyclohexenyl-nukleinsyreanaloger
|
|
US20110257251A1
(en)
|
2008-10-07 |
2011-10-20 |
Presidents And Fellows Of Harvard College |
Telomerase inhibitors and methods of use thereof
|
|
EA022418B1
(ru)
|
2008-10-22 |
2015-12-30 |
Кварк Фармасьютикалс, Инк. |
Способы лечения заболеваний глаз
|
|
EP2447274B1
(en)
|
2008-10-24 |
2017-10-04 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
|
EP2358397B1
(en)
|
2008-10-24 |
2020-01-01 |
Ionis Pharmaceuticals, Inc. |
5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
|
|
CN102282155B
(zh)
|
2008-12-02 |
2017-06-09 |
日本波涛生命科学公司 |
磷原子修饰的核酸的合成方法
|
|
CA2747999A1
(en)
|
2008-12-23 |
2010-07-01 |
Girindus America, Inc. |
Sulfurizing reagents and their use for oligonucleotides synthesis
|
|
WO2010080953A1
(en)
|
2009-01-08 |
2010-07-15 |
Isis Pharmaceuticals, Inc. |
Transgenic murine model of human lipoprotein metabolism, hypercholesterolemia and cardiovascular disease
|
|
KR20100087540A
(ko)
|
2009-01-28 |
2010-08-05 |
삼성전자주식회사 |
잉크젯 기록용 잉크 조성물
|
|
US20120264806A1
(en)
|
2009-02-06 |
2012-10-18 |
Bennett C Frank |
Oligomeric compounds and excipients
|
|
CA2752694A1
(en)
|
2009-02-10 |
2010-08-19 |
Idera Pharmaceuticals, Inc. |
Synthetic rna-based agonists of tlr7
|
|
JP5766617B2
(ja)
|
2009-02-20 |
2015-08-19 |
ユニバーシティ・オブ・カンザス |
修飾された糖部分を有するノボビオシン類似体
|
|
WO2010101951A1
(en)
|
2009-03-02 |
2010-09-10 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid chemical modifications
|
|
WO2010107838A1
(en)
|
2009-03-16 |
2010-09-23 |
Isis Pharmaceuticals, Inc. |
Targeting apolipoprotein b for the reduction of apolipoprotein c-iii
|
|
WO2010113937A1
(ja)
|
2009-03-31 |
2010-10-07 |
武田薬品工業株式会社 |
ヌクレオシドの製造方法
|
|
WO2010118263A1
(en)
|
2009-04-08 |
2010-10-14 |
University Of Massachusetts |
Single-nucleotide polymorphism (snp) targeting therapies for the treatment of huntington's disease
|
|
WO2010120262A1
(en)
|
2009-04-14 |
2010-10-21 |
Smith Holdings, Llc |
Methods and compositions for the treatment of medical conditions involving cellular programming
|
|
US9260493B2
(en)
|
2009-05-07 |
2016-02-16 |
The Regents Of The University Of California |
Transducible delivery of nucleic acids using modified dsRNA binding domains
|
|
KR20120052909A
(ko)
|
2009-06-01 |
2012-05-24 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
핵산 수송용 조성물 및 이의 사용 방법
|
|
PT2437753T
(pt)
|
2009-06-05 |
2016-11-23 |
Infectious Disease Res Inst |
Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
|
|
US8980853B2
(en)
|
2009-06-17 |
2015-03-17 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of SMN2 splicing in a subject
|
|
JP5670097B2
(ja)
|
2009-06-19 |
2015-02-18 |
花王株式会社 |
二層分離型毛髪化粧料
|
|
JPWO2010150789A1
(ja)
|
2009-06-23 |
2012-12-10 |
武田薬品工業株式会社 |
核酸の合成法
|
|
WO2011005764A1
(en)
|
2009-07-06 |
2011-01-13 |
Ada Technologies, Inc. |
Electrochemical device and method for long-term measurement of hypohalites
|
|
CA2767253A1
(en)
|
2009-07-06 |
2011-01-13 |
Ontorii, Inc. |
Novel nucleic acid prodrugs and methods of use thereof
|
|
US8927513B2
(en)
|
2009-07-07 |
2015-01-06 |
Alnylam Pharmaceuticals, Inc. |
5′ phosphate mimics
|
|
EP2451974A2
(en)
|
2009-07-08 |
2012-05-16 |
Idera Pharmaceuticals, Inc. |
Oligonucleotide-based compounds as inhibitors of toll-like receptors
|
|
EP2458005A1
(en)
|
2009-07-23 |
2012-05-30 |
Galaxy Pharma Inc. |
Fgf21 cis-element binding substance
|
|
WO2011015573A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
|
WO2011015572A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
|
UA107360C2
(en)
|
2009-08-05 |
2014-12-25 |
Biogen Idec Inc |
Bicyclic aryl sphingosine 1-phosphate analogs
|
|
WO2011017521A2
(en)
|
2009-08-06 |
2011-02-10 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
|
US8927553B2
(en)
|
2009-08-10 |
2015-01-06 |
Daljit Singh Dhanoa |
Deuterium-enriched alkyl sulfonamides and uses thereof
|
|
CN102625809B
(zh)
|
2009-09-11 |
2015-06-24 |
Isis制药公司 |
亨廷顿表达的调节
|
|
JP5878758B2
(ja)
|
2009-09-16 |
2016-03-08 |
株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ |
Ｒｎａ及びその誘導体合成のための新規保護基
|
|
US20120270929A1
(en)
|
2009-09-25 |
2012-10-25 |
Isis Pharmaceuticals, Inc. |
Modulation of ttc39 expression to increase hdl
|
|
WO2011045702A1
(en)
|
2009-10-15 |
2011-04-21 |
Pfizer Inc. |
Pyrrolo[2,3-d] pyrimidine compounds
|
|
TWI475051B
(zh)
|
2009-11-18 |
2015-03-01 |
Kao Corp |
Organic polysiloxane
|
|
JP5809408B2
(ja)
|
2009-11-25 |
2015-11-10 |
花王株式会社 |
毛髪化粧料
|
|
EP2512246B1
(en)
|
2009-12-17 |
2015-09-30 |
Merck Sharp & Dohme Corp. |
Aminopyrimidines as syk inhibitors
|
|
JP2013515953A
(ja)
|
2009-12-28 |
2013-05-09 |
アチラ ラボズ プライベート リミテッド |
診断用ゲル組成物、前記診断用ゲル組成物の製造方法
|
|
WO2011085271A2
(en)
|
2010-01-08 |
2011-07-14 |
Isis Pharmaceuticals, Inc. |
Modulation of angiopoietin-like 3 expression
|
|
US8750507B2
(en)
|
2010-01-25 |
2014-06-10 |
Cisco Technology, Inc. |
Dynamic group creation for managed key servers
|
|
ES2733708T3
(es)
|
2010-02-08 |
2019-12-02 |
Ionis Pharmaceuticals Inc |
Reducción selectiva de variantes alélicas
|
|
EP3208347B1
(en)
|
2010-02-08 |
2019-08-14 |
Ionis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
|
JP5922587B2
(ja)
|
2010-02-10 |
2016-05-24 |
グラクソスミスクライン エルエルシー |
６−アミノ−２−｛［（１ｓ）−１−メチルブチル］オキシ｝−９−［５−（１−ピペリジニル）ペンチル］−７，９−ジヒドロ−８ｈ−プリン−８−オンマレイン酸塩
|
|
WO2011108682A1
(ja)
|
2010-03-05 |
2011-09-09 |
国立大学法人 東京大学 |
リボヌクレオシドホスホロチオエートの製造方法
|
|
WO2011127175A1
(en)
|
2010-04-06 |
2011-10-13 |
Isis Pharmaceuticals, Inc. |
Modulation of cd130 (gp130) expression
|
|
EP2556159A1
(en)
|
2010-04-07 |
2013-02-13 |
Isis Pharmaceuticals, Inc. |
Modulation of cetp expression
|
|
WO2011133871A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
5'-end derivatives
|
|
US8993738B2
(en)
|
2010-04-28 |
2015-03-31 |
Isis Pharmaceuticals, Inc. |
Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
|
|
EP3091027B1
(en)
|
2010-04-28 |
2018-01-17 |
Ionis Pharmaceuticals, Inc. |
5' modified nucleosides and oligomeric compounds prepared therefrom
|
|
US20130156845A1
(en)
|
2010-04-29 |
2013-06-20 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
|
US8906607B2
(en)
|
2010-04-30 |
2014-12-09 |
Cellectis |
Method for modulating double-strand break-induced homologous recombination
|
|
GB201008902D0
(en)
|
2010-05-27 |
2010-07-14 |
Imp Innovations Ltd |
Membrane enhanced polymer sythesis
|
|
EP2611927B1
(en)
|
2010-08-31 |
2018-08-01 |
Sirna Therapeutics, Inc. |
Novel single chemical entities and methods for delivery of oligonucleotides
|
|
DK2620428T3
(da)
|
2010-09-24 |
2019-07-01 |
Wave Life Sciences Ltd |
Asymmetrisk hjælpegruppe
|
|
WO2012043633A1
(ja)
|
2010-09-30 |
2012-04-05 |
独立行政法人国立精神・神経医療研究センター |
優性変異遺伝子発現抑制剤
|
|
KR101381048B1
(ko)
|
2010-10-20 |
2014-04-14 |
씨제이제일제당 (주) |
Ｏ-포스포세린 생산 균주 및 이로부터 생산된 ｏ-포스포세린으로부터 ｌ-시스테인 또는 이의 유도체의 생산방법
|
|
ES2663009T3
(es)
|
2010-10-29 |
2018-04-10 |
Sirna Therapeutics, Inc. |
Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
|
|
EP2638163B1
(en)
|
2010-11-12 |
2017-05-17 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
|
WO2012073857A1
(ja)
|
2010-11-30 |
2012-06-07 |
株式会社キラルジェン |
２'－ｏ－修飾ｒｎａ
|
|
US20140050778A1
(en)
|
2010-12-28 |
2014-02-20 |
University Of Rochester |
Nucleic acid binding compounds, methods of making, and use thereof
|
|
EP3467109A1
(en)
|
2011-02-08 |
2019-04-10 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
US9181544B2
(en)
|
2011-02-12 |
2015-11-10 |
University Of Iowa Research Foundation |
Therapeutic compounds
|
|
WO2012151324A1
(en)
|
2011-05-02 |
2012-11-08 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with usher syndrome
|
|
FR2975600B1
(fr)
|
2011-05-24 |
2013-07-05 |
Assist Publ Hopitaux De Paris |
Agents pour le traitement de tumeurs
|
|
JP6128529B2
(ja)
|
2011-07-19 |
2017-05-17 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
官能化核酸の合成のための方法
|
|
US9885082B2
(en)
|
2011-07-19 |
2018-02-06 |
University Of Idaho |
Embodiments of a probe and method for targeting nucleic acids
|
|
DK2742135T4
(da)
|
2011-08-11 |
2020-07-13 |
Ionis Pharmaceuticals Inc |
Bindingsmodificerede gapped oligomeriske forbindelser og anvendelser deraf
|
|
US9282242B2
(en)
|
2011-08-24 |
2016-03-08 |
Htc Corporation |
Method and electric device for taking panoramic photograph
|
|
US9976138B2
(en)
|
2011-08-29 |
2018-05-22 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
|
US20140080896A1
(en)
|
2011-08-30 |
2014-03-20 |
The Regents Of The University Of California |
Identification of small molecules that facilitate therapeutic exon skipping
|
|
WO2013030588A1
(en)
|
2011-08-31 |
2013-03-07 |
The University Of Manchester |
Method for diagnosing a neurodegenerative disease
|
|
WO2013036833A1
(en)
|
2011-09-09 |
2013-03-14 |
Mayo Foundation For Medical Education And Research |
Detecting frontotemporal dementia and amyotrophic lateral sclerosis
|
|
EP2785729B1
(en)
|
2011-11-30 |
2020-11-04 |
Sarepta Therapeutics, Inc. |
Oligonucleotides for treating expanded repeat diseases
|
|
DK2790736T3
(en)
|
2011-12-12 |
2018-05-07 |
Oncoimmunin Inc |
In vivo delivery of oligonucleotides
|
|
CN102675386B
(zh)
|
2011-12-24 |
2014-07-02 |
河南科技大学 |
一种龙胆苦苷分离提纯方法
|
|
US8957042B2
(en)
|
2012-03-07 |
2015-02-17 |
The Texas A&M University System |
Cancer treatment targeting non-coding RNA overexpression
|
|
EP3210993B1
(en)
|
2012-03-13 |
2018-12-12 |
Gilead Sciences, Inc. |
2'- substituted carba-nucleoside analogs for antiviral treatment
|
|
KR20130114435A
(ko)
|
2012-04-09 |
2013-10-17 |
삼성전자주식회사 |
다수의 전극을 갖는 생분자 검출 장치
|
|
CN110025628B
(zh)
|
2012-04-23 |
2023-03-31 |
维科医疗有限公司 |
治疗神经肌肉障碍的具有改善特性的rna调节寡核苷酸
|
|
EA031301B1
(ru)
|
2012-05-22 |
2018-12-28 |
Иденикс Фармасьютикалз Ллс |
D-аминокислотные химические соединения для лечения заболеваний печени
|
|
IN2014DN10144A
(pt)
|
2012-05-30 |
2015-08-21 |
Hokkaido System Science Co Ltd |
|
|
SG11201500243WA
(en)
|
2012-07-13 |
2015-04-29 |
Shin Nippon Biomedical Lab Ltd |
Chiral nucleic acid adjuvant
|
|
KR101850319B1
(ko)
|
2012-07-13 |
2018-04-20 |
웨이브 라이프 사이언시스 리미티드 |
비대칭 보조 그룹
|
|
CN112007045A
(zh)
|
2012-07-13 |
2020-12-01 |
波涛生命科学有限公司 |
手性控制
|
|
EP4253395A3
(en)
|
2012-08-06 |
2023-11-29 |
Alnylam Pharmaceuticals, Inc. |
Processes for the preparation of carbohydrate conjugated rna agents
|
|
KR102237882B1
(ko)
|
2012-08-15 |
2021-04-07 |
아이오니스 파마수티컬즈, 인코포레이티드 |
변형된 캡핑 프로토콜을 이용하는 올리고머 화합물 제조 방법
|
|
EP2906256B1
(en)
|
2012-10-12 |
2018-08-22 |
Ionis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
|
JP6570447B2
(ja)
|
2012-10-15 |
2019-09-04 |
アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
Ｃ９ｏｒｆ７２発現を調節するための組成物
|
|
WO2014062736A1
(en)
|
2012-10-15 |
2014-04-24 |
Isis Pharmaceuticals, Inc. |
Methods for monitoring c9orf72 expression
|
|
ES2762326T5
(es)
|
2012-10-15 |
2023-04-27 |
Ionis Pharmaceuticals Inc |
Métodos para modular la expresión de C9ORF72
|
|
EP2725029A1
(en)
|
2012-10-29 |
2014-04-30 |
Laboratoire Biodim |
New antibacterial compounds and biological applications thereof
|
|
JP2015535261A
(ja)
|
2012-10-29 |
2015-12-10 |
コクリスタル ファーマ，インコーポレイテッド |
ウイルス感染及び癌の治療のためのピリミジンヌクレオチド及びその一リン酸プロドラッグ
|
|
WO2014069520A1
(ja)
|
2012-10-31 |
2014-05-08 |
武田薬品工業株式会社 |
新規修飾核酸
|
|
NZ708171A
(en)
|
2012-11-15 |
2019-11-29 |
Roche Innovation Ct Copenhagen As |
Oligonucleotide conjugates
|
|
EP2922955B1
(en)
|
2012-11-26 |
2019-03-06 |
Roche Innovation Center Copenhagen A/S |
Compositions and methods for modulation of fgfr3 expression
|
|
EP2935304A1
(en)
|
2012-12-19 |
2015-10-28 |
IDENIX Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
|
WO2014118272A1
(en)
|
2013-01-30 |
2014-08-07 |
Santaris Pharma A/S |
Antimir-122 oligonucleotide carbohydrate conjugates
|
|
DK2951305T3
(en)
|
2013-01-30 |
2018-10-29 |
Hoffmann La Roche |
LNA oligonucleotide KULHYDRATKONJUGATER
|
|
ES2817050T3
(es)
|
2013-02-04 |
2021-04-06 |
Ionis Pharmaceuticals Inc |
Compuestos antisentido selectivos y usos de los mismos
|
|
JP6613143B2
(ja)
|
2013-02-22 |
2019-11-27 |
サーナ・セラピューティクス・インコーポレイテッド |
２’ヌクレオシド間結合を含有する低分子干渉核酸（ｓｉＮＡ）分子
|
|
CA2907750A1
(en)
|
2013-03-28 |
2014-10-02 |
Syngenta Participations Ag |
Methods of controlling neonicotinoid resistant pests
|
|
CN105120667A
(zh)
|
2013-03-28 |
2015-12-02 |
先正达参股股份有限公司 |
控制新烟碱抗性有害生物的方法
|
|
ES2730015T3
(es)
|
2013-05-01 |
2019-11-07 |
Ionis Pharmaceuticals Inc |
Composiciones y métodos para modular expresión de HBV y de TTR
|
|
DK3015467T3
(da)
|
2013-05-24 |
2025-02-10 |
Ajinomoto Kk |
Morpholino-oligonukleotidfremstillingsfremgangsmåde
|
|
US20160130582A1
(en)
|
2013-05-24 |
2016-05-12 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide modulators of b-cell cll/lymphoma 11a (bcl11a) and uses thereof
|
|
CA2916252A1
(en)
|
2013-06-21 |
2014-12-24 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of target nucleic acids
|
|
US9879265B2
(en)
|
2013-06-27 |
2018-01-30 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugates
|
|
TW202246503A
(zh)
|
2013-07-19 |
2022-12-01 |
美商百健Ｍａ公司 |
用於調節τ蛋白表現之組合物
|
|
JP6697384B2
(ja)
|
2013-07-25 |
2020-05-20 |
イグジキュア, インコーポレーテッドExicure, Inc. |
予防的および治療的使用のための免疫刺激剤としての球状の核酸ベース構築物
|
|
EP3027617A4
(en)
|
2013-07-31 |
2017-04-12 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
|
BR112016004352A2
(pt)
|
2013-09-06 |
2017-09-12 |
Syngenta Participations Ag |
compostos inseticidas
|
|
WO2015051169A2
(en)
|
2013-10-02 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
|
BR112016007255A2
(pt)
|
2013-10-03 |
2017-09-12 |
Moderna Therapeutics Inc |
polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
|
|
WO2015051366A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Novel formats for organic compounds for use in rna interference
|
|
EP3055414A4
(en)
|
2013-10-11 |
2017-07-19 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating c9orf72 expression
|
|
US20160230172A1
(en)
|
2013-10-14 |
2016-08-11 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
ES2747260T3
(es)
|
2013-10-14 |
2020-03-10 |
Ionis Pharmaceuticals Inc |
Métodos para modular la expresión de transcrito antisentido C9ORF72
|
|
US10369201B2
(en)
|
2013-11-11 |
2019-08-06 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating Huntington's disease
|
|
WO2015071388A1
(en)
|
2013-11-14 |
2015-05-21 |
Roche Innovation Center Copenhagen A/S |
Apob antisense conjugate compounds
|
|
EP3053585A1
(en)
|
2013-12-13 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules and uses thereof
|
|
WO2015108048A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
|
EP3095461A4
(en)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
|
|
JPWO2015108046A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
|
|
EP4137572A1
(en)
|
2014-01-16 |
2023-02-22 |
Wave Life Sciences Ltd. |
Chiral design
|
|
ES2856403T3
(es)
|
2014-03-18 |
2021-09-27 |
Univ Massachusetts |
Composiciones a base de rAAV y procedimientos para el tratamiento de la esclerosis lateral amiotrofica
|
|
US9926556B2
(en)
|
2014-04-28 |
2018-03-27 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
|
BR122020024443B1
(pt)
|
2014-05-01 |
2022-02-22 |
Ionis Pharmaceuticals, Inc |
Composto e composição farmacêutica para modulação da expressão de angptl3
|
|
AU2015255877B2
(en)
|
2014-05-08 |
2020-03-26 |
Chdi Foundation, Inc. |
Methods and compositions for treating huntington's disease
|
|
AU2015264263B2
(en)
|
2014-05-20 |
2021-08-05 |
University Of Iowa Research Foundation |
Huntington's disease therapeutic compounds
|
|
US20160017327A1
(en)
|
2014-07-11 |
2016-01-21 |
The Johns Hopkins University |
Phosphorodiamidate morpholino oligomers (pmos) and their use in suppression of mutant huntingtin expression and attenuation of neurotoxicity
|
|
JP2017524357A
(ja)
|
2014-07-16 |
2017-08-31 |
モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． |
キメラポリヌクレオチド
|
|
EP2982758A1
(en)
|
2014-08-04 |
2016-02-10 |
Centre Hospitalier Universitaire Vaudois (CHUV) |
Genome editing for the treatment of huntington's disease
|
|
CA2956554C
(en)
|
2014-08-07 |
2022-03-01 |
Takeda Pharmaceutical Company Limited |
Preparation of cationic lipid compounds and their salts as nucleic acid carriers
|
|
WO2016024205A1
(en)
|
2014-08-15 |
2016-02-18 |
Pfizer Inc. |
Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
|
|
WO2016037191A1
(en)
|
2014-09-05 |
2016-03-10 |
Health Research, Inc. |
Use of huntingtin-derived plasmids and peptides for active immunization as a huntington's disease (hd) therapeutic
|
|
JP2017536119A
(ja)
|
2014-11-19 |
2017-12-07 |
ロシュ イノベーション センター コペンハーゲン エーエス |
キラルホスホロチオエート連結を含むｌｎａギャップマーオリゴヌクレオチド
|
|
JP6689279B2
(ja)
|
2014-12-16 |
2020-05-20 |
ロシュ イノベーション センター コペンハーゲン エーエス |
キラル毒性のスクリーニング方法
|
|
WO2016102664A1
(en)
|
2014-12-24 |
2016-06-30 |
Uniqure Ip B.V. |
Rnai induced huntingtin gene suppression
|
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
|
WO2016112132A1
(en)
|
2015-01-06 |
2016-07-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
US20180023081A1
(en)
|
2015-02-04 |
2018-01-25 |
Bristol-Myers Squibb Company |
Lna oligonucleotides with alternating flanks
|
|
US11761951B2
(en)
|
2015-02-04 |
2023-09-19 |
Bristol-Myers Squibb Company |
Methods of selecting therapeutic molecules
|
|
US10450563B2
(en)
|
2015-02-10 |
2019-10-22 |
Genzyme Corporation |
Variant RNAi
|
|
JP2018510621A
(ja)
|
2015-02-13 |
2018-04-19 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
パタチン様ホスホリパーゼドメイン含有３（ＰＮＰＬＡ３）ｉＲＮＡ組成物およびその使用方法
|
|
EP3262174A4
(en)
|
2015-02-23 |
2018-10-17 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for increasing antisense activity
|
|
WO2016141236A1
(en)
|
2015-03-03 |
2016-09-09 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating mecp2 expression
|
|
WO2016145142A1
(en)
|
2015-03-10 |
2016-09-15 |
Emory University |
Nucleotide and nucleoside therapeutics compositions and uses related thereto
|
|
WO2016154096A1
(en)
|
2015-03-20 |
2016-09-29 |
Ionis Pharmaceuticals, Inc. |
Modulation of smggds expression
|
|
AU2016244027B2
(en)
|
2015-04-03 |
2022-04-28 |
University Of Massachusetts |
Oligonucleotide compounds for targeting Huntingtin mRNA
|
|
US10851371B2
(en)
|
2015-04-10 |
2020-12-01 |
Ionis Pharmaceuticals, Inc. |
Modulation of SMN expression
|
|
SI3283080T1
(sl)
|
2015-04-16 |
2020-06-30 |
Ionis Pharmaceuticals, Inc. |
Sestavki za moduliranje izražanja C9ORF72
|
|
US10407678B2
(en)
|
2015-04-16 |
2019-09-10 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
|
AU2016285724A1
(en)
|
2015-06-29 |
2017-11-16 |
Ionis Pharmaceuticals, Inc. |
Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
|
|
IL256622B2
(en)
|
2015-07-10 |
2023-09-01 |
Ionis Pharmaceuticals Inc |
Modulators of diacyglycerol acyltransferase 2 (dgat2)
|
|
WO2017011286A1
(en)
|
2015-07-10 |
2017-01-19 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
|
|
WO2017015109A1
(en)
|
2015-07-17 |
2017-01-26 |
Alnylam Pharmaceuticals, Inc. |
Multi-targeted single entity conjugates
|
|
MA43072A
(fr)
|
2015-07-22 |
2018-05-30 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
|
US20180216114A1
(en)
|
2015-07-27 |
2018-08-02 |
Alnylam Pharmaceuticals, Inc. |
Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
|
|
HK1256683A1
(zh)
|
2015-07-31 |
2019-10-04 |
阿尔尼拉姆医药品有限公司 |
甲狀腺素運載蛋白(ttr)irna組合物及其治療或預防ttr相關疾病的使用方法
|
|
US20190055550A1
(en)
|
2015-08-24 |
2019-02-21 |
Roche Innovation Center Copenhagen A/S |
LNA-G Process
|
|
CA2996701C
(en)
|
2015-08-25 |
2024-05-28 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
|
|
PE20181131A1
(es)
|
2015-09-02 |
2018-07-17 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE ARNi PARA LIGANDO 1 DE MUERTE CELULAR PROGRAMADA 1 (PD-L1) Y METODOS DE USO DE LAS MISMAS
|
|
US10874686B2
(en)
|
2015-10-01 |
2020-12-29 |
Memorial Sloan-Kettering Cancer Center |
Anthranilyl-adenosinemonosulfamate analogs and uses thereof
|
|
WO2017059411A1
(en)
|
2015-10-01 |
2017-04-06 |
Memorial Sloan-Kettering Cancer Center |
Inhibitors of menaquinone biosynthesis
|
|
US10577388B2
(en)
|
2015-10-02 |
2020-03-03 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugation process
|
|
CR20180233A
(es)
|
2015-10-09 |
2018-05-25 |
Wave Life Sciences Ltd |
Composiciones oligonucleotídicas y sus métodos
|
|
EP3183347A4
(en)
|
2015-10-17 |
2018-04-18 |
Lifesplice Pharma LLC |
Splice modulating oligonucleotides and methods of use thereof
|
|
WO2017067970A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
In vitro toxicity screening assay
|
|
WO2017068087A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide detection method
|
|
US11260073B2
(en)
|
2015-11-02 |
2022-03-01 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating C90RF72
|
|
SG11201803951QA
(en)
|
2015-11-12 |
2018-06-28 |
Hoffmann La Roche |
Oligonucleotides for inducing paternal ube3a expression
|
|
CN108779132B
(zh)
|
2016-03-13 |
2022-04-15 |
波涛生命科学有限公司 |
用于亚磷酰胺和寡核苷酸合成的组合物和方法
|
|
SI3430141T1
(sl)
|
2016-03-14 |
2021-04-30 |
F. Hoffmann-La Roche Ag |
Oligonukleotidi za zmanjšanje izraženosti PD-L1
|
|
CN108779139A
(zh)
|
2016-03-18 |
2018-11-09 |
罗氏创新中心哥本哈根有限公司 |
酰基保护的l-lna-鸟嘌呤核苷单体
|
|
US11963972B2
(en)
|
2016-03-23 |
2024-04-23 |
Emory University |
Antiviral agents and nucleoside analogs for treatment of Zika virus
|
|
US20190142856A1
(en)
|
2016-04-13 |
2019-05-16 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing c9orf72 expression
|
|
US11248019B2
(en)
|
2016-04-14 |
2022-02-15 |
Hoffmann-La Roche Inc. |
Trityl-mono-GalNAc compounds and their use
|
|
MA45270A
(fr)
|
2016-05-04 |
2017-11-09 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
|
MA45290A
(fr)
|
2016-05-04 |
2019-03-13 |
Wave Life Sciences Ltd |
Procédés et compositions d'agents biologiquement actifs
|
|
JP7097820B2
(ja)
|
2016-05-12 |
2022-07-08 |
ロシュ イノベーション センター コペンハーゲン エーエス |
ヌクレオシドまたはオリゴヌクレオチドへの、立体的に規定されたオキサザホスホリジンホスホルアミダイト単量体のカップリングの増大法
|
|
CN109072234B
(zh)
|
2016-05-13 |
2022-11-29 |
豪夫迈·罗氏有限公司 |
基于蛋白质的样品采集基质和装置
|
|
EP3458464A1
(en)
|
2016-05-18 |
2019-03-27 |
ETH Zurich |
Stereoselective synthesis of phosphorothioate oligoribonucleotides
|
|
CN109562122A
(zh)
|
2016-06-03 |
2019-04-02 |
波涛生命科学有限公司 |
寡核苷酸、组合物及其方法
|
|
EP3473270B1
(en)
|
2016-06-20 |
2022-11-30 |
Genahead Bio, Inc. |
Antibody-drug conjugate
|
|
WO2018022473A1
(en)
|
2016-07-25 |
2018-02-01 |
Wave Life Sciences Ltd. |
Phasing
|
|
MA46905A
(fr)
|
2016-11-23 |
2019-10-02 |
Wave Life Sciences Ltd |
Compositions et procédés de synthèse de phosphoramidites et d'oligonucléotides
|
|
EP3630199A4
(en)
|
2017-06-02 |
2021-11-10 |
Wave Life Sciences Ltd. |
COMPOSITIONS OF OLIGONUCLEOTIDES AND THEIR METHODS OF USE
|
|
TW201904587A
(zh)
|
2017-06-02 |
2019-02-01 |
新加坡商波濤生命科學有限公司 |
寡核苷酸組合物及其使用方法
|
|
WO2018223073A1
(en)
|
2017-06-02 |
2018-12-06 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
US11718638B2
(en)
|
2017-06-21 |
2023-08-08 |
Wave Life Sciences Ltd. |
Compounds, compositions and methods for synthesis
|
|
EP3664816A4
(en)
|
2017-08-08 |
2021-05-19 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND RELATED PROCESSES
|
|
AU2018333065B2
(en)
|
2017-09-18 |
2024-04-18 |
Wave Life Sciences Ltd. |
Technologies for oligonucleotide preparation
|
|
SG11202001783YA
(en)
|
2017-10-12 |
2020-03-30 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods thereof
|
|
SG11202009877XA
(en)
|
2018-04-12 |
2020-11-27 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods of use thereof
|
|
EP3790596A4
(en)
|
2018-05-11 |
2022-04-06 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE
|
|
SG11202105626TA
(en)
|
2018-12-06 |
2021-06-29 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods thereof
|
|
MX2021009178A
(es)
|
2019-02-01 |
2021-09-08 |
Wave Life Sciences Ltd |
Composiciones de oligonucleotidos y metodos de las mismas.
|
|
MX2021011351A
(es)
|
2019-03-20 |
2021-12-10 |
Wave Life Sciences Ltd |
Tecnologias utiles para la preparacion de oligonucleotidos.
|
|
JPWO2020196662A1
(pt)
|
2019-03-25 |
2020-10-01 |
|
|
|
SG11202111387YA
(en)
|
2019-04-25 |
2021-11-29 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods of use thereof
|
|
US20250051778A1
(en)
|
2019-04-25 |
2025-02-13 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
CN114502177A
(zh)
|
2019-05-09 |
2022-05-13 |
波涛生命科学有限公司 |
寡核苷酸组合物及其使用方法
|
|
US20240175016A1
(en)
|
2019-10-06 |
2024-05-30 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
WO2021071858A1
(en)
|
2019-10-06 |
2021-04-15 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
US20230295619A1
(en)
|
2020-03-01 |
2023-09-21 |
Abbie Madeline Maguire |
Oligonucleotide compositions and methods thereof
|
|
CA3176986A1
(en)
|
2020-05-22 |
2021-11-25 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
EP4153747A2
(en)
|
2020-05-22 |
2023-03-29 |
Wave Life Sciences Ltd. |
Double stranded oligonucleotide compositions and methods relating thereto
|
|
EP4200616A1
(en)
|
2020-08-24 |
2023-06-28 |
Wave Life Sciences Ltd. |
Immunoassays for detecting wild type huntingtin protein and methods of treatment employing such immunoassays
|
|
EP4199957A4
(en)
|
2020-08-24 |
2024-10-02 |
Wave Life Sciences Ltd. |
NON-HUMAN CELLS AND ANIMALS ENGINEERED TO EXPRESS ADAR1 AND THEIR USES
|
|
US20230416847A1
(en)
|
2020-09-24 |
2023-12-28 |
Mayo Foundation For Medical Education And Research |
Screening platforms
|
|
CN116507724A
(zh)
|
2020-11-08 |
2023-07-28 |
波涛生命科学有限公司 |
寡核苷酸组合物及其方法
|
|
MX2023005326A
(es)
|
2020-11-08 |
2023-07-31 |
Wave Life Sciences Ltd |
Composiciones de oligonucleótidos y métodos de las mismas.
|
|
WO2023049477A2
(en)
|
2021-09-26 |
2023-03-30 |
Wave Life Sciences Ltd. |
Compositions for editing mecp2 transcripts and methods thereof
|
|
KR20240063964A
(ko)
|
2021-09-26 |
2024-05-10 |
웨이브 라이프 사이언시스 리미티드 |
올리고뉴클레오티드 조성물 및 이의 방법
|
|
EP4422645A2
(en)
|
2021-10-27 |
2024-09-04 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
WO2023075766A1
(en)
|
2021-10-27 |
2023-05-04 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
JP2025506484A
(ja)
|
2022-02-11 |
2025-03-11 |
ウェイブ ライフ サイエンシズ リミテッド |
キラル化合物の立体選択的技術
|
|
CN119137134A
(zh)
|
2022-03-02 |
2024-12-13 |
波涛生命科学有限公司 |
寡核苷酸组合物及其用于外显子跳跃的方法
|
|
KR20250004787A
(ko)
|
2022-04-15 |
2025-01-08 |
웨이브 라이프 사이언시스 리미티드 |
올리고뉴클레오티드 조성물 및 이와 관련된 방법
|
|
WO2023220440A1
(en)
|
2022-05-12 |
2023-11-16 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
WO2024035946A1
(en)
|
2022-08-11 |
2024-02-15 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|